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Abstract
A Synthetic lethal (SL) interaction involves a pair of genes (geneA and geneB) where inhi-
bition of either geneA or geneB individually has no effect on cell viability, but the inhibition
of both geneA and geneB causes cell death. SL interactions that occur between gene pairs
can be exploited for cancer therapeutics. Studies in the model eukaryote yeast have identi-
fied approximately 550,000 negative genetic interactions that have been extensively applied
to characterize novel pathways and gene functions. In the context of this thesis, a nega-
tive genetic interaction is the equivalent of a SL interaction. Harnessing the vast available
knowledge of yeast genetics, we generated a Humanized Yeast Genetic Interaction Network
(HYGIN) for 1,009 human genes with yeast orthologs and 10,419 interactions. Through the
addition of patient-data from The Cancer Genome Atlas (TCGA), we generated a breast
cancer specific subnetwork. Specifically, by comparing 1,009 genes in HYGIN to genes that
were down-regulated in breast cancer, we identified 15 breast cancer genes with 130 potential
SL interactions. Interestingly, 32 of the 130 predicted SL interactions occurred with FBXW7,
a well-known tumor suppressor that functions as a substrate-recognition protein within the
SKP/CUL1/F-Box ubiquitin ligase complex for degradation through the proteasome. Vali-
dation of these SL interactions using chemical genetic data indicate that patients with loss
of FBXW7 may respond to treatment with drugs like Selumitinib or Cabozantinib. Taken
together, our patient-data driven interpretation of HYGIN represents a novel strategy to
uncover therapeutically relevant drug targets.
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Chapter 1
Introduction
Genetically, cancer is a complex disease with no two patients exhibiting the same genetic
profiles of tumors. Recent advances in tumor sequencing and identification of key driver genes
has allowed the development of more targeted treatment strategies by leveraging individual
patient genetics [10]. However, the druggability of these targets becomes challenging if these
genes are not expressed or are down-regulated in certain cancers.
Synthetic lethality takes advantage of functional genetic interactions between gene pairs to
develop targeted therapies. Genetic interactions are the phenomenon where two or more gene
products interact with one another that results in a deviation of the expected phenotype [78].
Synthetic lethal (SL) interactions are beginning to be appreciated as a method for identifying
druggable targets [30, 89, 101]. Inhibiting the synthetic lethal partner with a therapeutic
drug selectively eliminates cancer cells leaving normal cells largely unaffected. By exploiting
these synthetic lethal interactions, we can maximize the efficiency of personalized treatment
options (novel drugs, or repurposed drugs) and, potentially, minimize the side effects that a
patient experiences as a result of the therapy. Although the advent of genome-wide shRNA
and CRISPR-Cas9 screens have provided the specificity needed to perform the comprehensive
epistasis mapping on any number of chosen gene pairs [48, 90, 127], experimentally testing all
possible gene pairs across multiple cell types to identify SL is laborious and time-consuming.
Previously, yeast SL genetic interaction data has been used to identify SL gene interac-
tions in humans [27, 76, 113]. These yeast-directed approaches have helped uncover several
druggable interactions in human cells. For example, McManus et al. identified the first
humanized synthetic lethal interactions of RAD54B -deficient human colorectal cancer cells
by mapping the corresponding yeast synthetic lethal interactions to human cancer cells [76].
Thus, rather than evaluating all human SL interactions, evaluating some in a yeast context
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provided valuable insights into SL interactions in cancer. This approach reduces the dimen-
sionality of searching for SL interactions in humans by reducing the total set of potential
genes that can interact with one another to only those that have yeast orthologs. As a result,
since the yeast genome is substantially smaller than the human genome and only a fraction
of yeast genes have human orthologs, the total sample space for potential SL interactions in
humans is reduced.
Although using pre-existing experimental data from yeast is extremely useful, results
generated from mapping yeast data to humans does not provide a comprehensive picture
of the human SL landscape. It turns out that the greatest strength of using yeast data
to identify human SL interactions (reducing the dimensionality of the problem) is also it’s
greatest weakness: eliminating the majority of human genes from the analysis. The human
genome contains approximately 20,000 genes and the yeast genome approximately 6,000.
Given the evolutionary distance between yeast and humans, it is not surprising that there
are only around 2,000 yeast genes that have human orthologs. As a result, if we are at
most examining these 2,000 human genes with yeast orthologs for SL interactions, we are
only evaluating 1/10 of the human genome. Therefore, using model species such as yeast is
extremely useful for advancing the discovery of novel SL interactions in humans; however,
caution must be taken when interpreting the results as there could exist many SL interactions
between human genes without yeast orthologs.
The Cell Map contains a global genetic interaction map for Saccharomyces cerevisiae
[23]. Using more than 23 million experimentally generated double mutants, approximately
550,000 negative and 350,000 positive interactions were reported in The Cell Map. Previous
work by Deshpande et al. made use of an older version of this data [22], and was motiva-
tion for this study. Having identified potential problems with the Deshpande et al. work,
this thesis aimed to improve upon their strategy for generating a human network of po-
tential SL interactions based on previously experimentally validated yeast interaction data.
Harnessing the vast available knowledge of yeast genetics and using yeast-human ortholog
mapping, we generated a humanized yeast genetic interaction network (HYGIN) that has
the potential to identify novel cancer-specific synthetic lethal interactions and novel cancer
treatment strategies. Since no cancer data has been used in the generation of HYGIN any
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cancer specific data can be incorporated to generate a subset of SL interactions in humans
that are cancer specific. Breast cancer is the third most common type of cancer in Canada
accounting for more than 25% of all new cases of cancer in women and 13% of all cancers
in Canada. This network is then integrated with patient data from The Cancer Genome At-
las (TCGA) (https://cancergenome.nih.gov/) to identify genes that are down-regulated
in breast cancer to provide a breast cancer-focused version of HYGIN. The breast cancer
specific subnetwork contains 130 SL interactions with 15 genes that were identified to be
down-regulated in breast cancer and 115 other genes in HYGIN. Of these 130 SL interac-
tions, we predict 32 novel synthetic lethal interactions of the tumor suppressor FBXW7 that
could be exploited for patient-specific cancer therapeutics using previously identified or novel
drugs.
The remainder of this thesis is organized as follows. Background information on cancer,
yeast as a model organism, synthetic lethality, computational approaches to synthetic lethal-
ity, data sources for computational studies and FBXW7 is given in Chapter 2. Chapter 3
articulates the research hypothesis of this thesis. The data used and methodology for gen-
erating HYGIN, initial data analysis techniques, statistical analyses used, validation of the
network, and drug analyses are covered in Chapter 4. Results from evaluating HYGIN and
the breast cancer subnetwork are presented in Chapter 5. Chapter 6 analyzes and interprets
the results present in Chapter 5, discusses the shortcomings of previous work and compares
HYGIN to it. Finally, Chapter 7 summarizes the conclusions of this work and proposes future
research endeavours using HYGIN. Currently a manuscript describing this work is in the final
stages of preparation for journal publication. The majority of the manuscript is integrated
into this thesis document as Chapter 1, Sections 4.1 – 4.3, Sections 4.5 – 4.6, Chapter 5,
portions of Section 6.1 and Section 6.4.
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Chapter 2
Background
This section provides the necessary background material for understanding the research
that is present in this thesis. Section 2.1 provides a brief introduction to cancer. Section 2.1.1
gives some background on the molecular classification of cancers, and section 2.1.2 provides
an overview of information pertaining to breast cancer. Section 2.2 gives an introduction
to yeast as a model organism, and section 2.2.1 discusses orthology and different ways that
genes can be mapped between species. Section 2.3 contains a short background on synthetic
lethality, it’s applications and previous work. A survey of previous computational approaches
to synthetic lethality can be found in section 2.4. Section 2.5 provides background information
on the sources of data used in this thesis: 2.5.1; the Cell Map, 2.5.2; InParanoid, 2.5.3;
SynLethDB, 2.5.4; the cancer genome atlas. Finally, section 2.6 provides an introduction to
the tumor suppressor FBXW7 and it’s role in cancer.
2.1 Cancer
Cancer is an extremely complex group of diseases that are the result of loss of control over
cell division and cell growth. Recent statistics from the Canadian Cancer Society suggest
that 1 in 2 Canadians will develop cancer in their lifetime, and 1 in 4 will die from it [107].
With such a high incidence rate in the population, it is necessary to identify and understand
the mechanisms of cancer so that patients can receive better treatment. Since there are
many different ways that a healthy cell can transform into a tumor cell, the identification of
drug targets and personalized therapeutics is difficult. As a result, researchers are leveraging
genetics research to develop personalized approaches to cancer therapy.
There are many different ways that cancer can arise in a cell leading to the complicated
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task of identifying which genes are associated with which cancers. With advances in molecular
biology techniques and genetics, researchers have identified two major types of genes that con-
tribute to cancer: tumor suppressor genes (TSGs) and oncogenes. TSGs are a class of genes
that under normal cellular function can repair damaged DNA (e.g. ataxia-telangiectasia-
mutated gene product (ATM ), breast cancer protein (BRCA), and p53 ), regulate cell di-
vision (e.g. alternate reading frame (ARF ), RIZ1, p27, and p53 ), and control apoptosis
(regulated cell death) (e.g. adenomatous polyposis coli (APC), cluster of differentiation 95
(CD95 ), and p53 ) [115]. However, in cases where TSGs are mutated or deleted these cell
processes are no longer regulated and can lead to cancer. A classic example of a TSG is the
nuclear transcription factor p53 [87]. Genetic analysis of multiple cancer types suggests that
p53 has a loss of function mutation in more than 50% of cancers [5, 54, 82, 116]. In these
cases, p53 loses the ability to repair damaged DNA and initiate cell apoptosis. There have
even been studies in mice that show that mice with mutations to p53 spontaneously develop
tumors [31]. There are several different genetic means by which genes can lose expression and
lead to cancer: mutations, deletions in the upstream region responsible for the regulation of
a gene, whole gene deletions due to deletions on a chromosomal level, siRNA’s, and most
prominently DNA methylation resulting in a loss of gene expression [9, 33, 60, 79, 132].
On the other hand, oncogenes are the key drivers of tumor growth and are often expressed
at high levels in tumor cells [67]. Oncogenes can cause chromosome instability and unsched-
uled cell growth and have been shown not only to be involved in cancer development, but also
in cancer maintenance [125]. They have also been shown to play an important role in cancer
cell metabolism where they aid tumors in meeting their nutritional retirements for growth,
contributing to the notion that cancer is a metabolic disease [80]. However, oncogenes have
to be activated in order to cause cancer. Proto-oncogenes are normally expressed genes in
the cell that have the capacity to cause cancer when they are activated to become oncogenes
[121]. For example, under normal cellular conditions, the highly regulated MYC (a tran-
scription factor) proto-oncogene does not have the capacity to initiate cancer development.
However, a mutation within the regulatory region for MYC could increase its expression
making it an oncogene [25].
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2.1.1 Molecular classification of cancers
Cancers tend to be classified based on the tissue or cell type that they were isolated from
(e.g. breast, prostate, lung, esophageal, or pancreatic cancers). Though this method has
been useful for doctors, patients, and researchers in the past, recent advances in genome
sequencing technology have shed light onto the genetics of these cancers and potentially
provided a complimentary means of classifying them for treatment [24, 53]. A recent study
has shown that 43% of cancer cases on average are more similar to cancers from other tissue
types than they are similar to other cancers from the same tissue [24]. For example, Heim et.
al report that 14% of breast cancer cases are more closely related to ovarian cancer than they
are to breast cancer. Furthermore, another study by Hoadley et al examined 12 cancer types
and identified 11 major classification subtypes based on genetic analysis [53]. Although 5 of
the subtypes contained cancer cases that were almost exactly the same as classifying cancers
by tissue, it was found that cases of bladder cancer could be split into three different subtypes
[53]. Classifying cancers into types based on genetics rather than tissue type provides a novel
categorization for researchers that hopefully results in the re-purposing of cancer therapeutics
from tissue types of cancer to molecular types.
Hoadley et al. released a more recent article in 2018 that expanded on their previous
research and included 33 types of cancer and more than 10,000 tumors [52]. The updated
research concluded that molecular tumor classification is influenced by cell-of-origin, but is
not determined by it [52]. It is important to maintain the current cell-of-origin classification
system for cancer as it allows researchers and doctors to understand what is happening in
the body and how it is affecting physiology in a patient. However, molecular classification
systems are also important as they provide doctors with novel treatment strategies that
might not have been identified through cell-of-origin typing. Ultimately, neither of these two
classifications systems is perfect; both have their merits and are necessary for prioritizing
patient care and effective treatment.
Although cancer therapies have come a long way since they were first introduced, there
are still negative side effects that impact patients undergoing treatment. As a result, there
is a need for new therapeutics that specifically target cancer cells, while minimizing negative
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side effects. By grouping cancers based on their genetic similarities, researchers can use
existing therapeutic strategies that target a well know cancer-associated gene in one cancer
and apply it to genetically similar cancers. Research efforts towards patient-specific therapies
often evaluate known therapeutics and their effectiveness for patients with specific genetic
profiles or biomarkers. This is an enticing research avenue that can potentially reduce the
negative side effects of treatment and eliminates superfluous, ineffective treatments.
With advances in genome sequencing technology and the ability to identify cancer biomark-
ers through genome sequencing, personalized medicine is now becoming a reality. Patient-
specific therapeutics are starting to become common practice in many cancer treatment
strategies [124, 131]. These approaches involve selecting therapeutics based on the genetic
profiles of the patients and their tumor(s). Identifying patient-specific novel druggable targets
in cancer is still costly with respect to time and resources. As a result, research efforts are
turning to computational techniques to predict patient specific druggable genes for efficient
cancer therapeutics.
2.1.2 Breast cancer
Breast cancer is the third most common form of cancer in Canada, accounting for more than
25% of new cases of cancer in women in 2017 [107]. There are 5 intrinsic types of breast cancer:
luminal A, luminal B, triple-negative breast cancer (TNBC), human epidermal growth factor
rceptor 2 enriched (HER2-enriched), and normal-like [14, 85, 93, 110]. Luminal A breast can-
cer is characterized by the presence of the estrogen rceptor (ER) and the progesterone rceptor
(PR), the absence of HER2 (abbreviated ER+/PR+/HER2-), and low levels of the Ki-67
protein. This type of breast cancer has the best prognosis among breast cancers [85]. Luminal
B breast cancer is ER+/PR+, either HER2 positive or negative (ER+/PR+/HER2+/-) and
has high levels of Ki-67 [85]. In contrast, TNCB is ER-/PR-/HER2- and represents 10-20%
of breast cancers [135]. HER2-enriched breast cancer is ER-/PR-/HER2+ and tends to grow
faster and have a worse prognosis than luminal A and luminal B breast cancers [85]. Finally,
normal-like breast cancer is ER+/PR+/HER2- and very similar to luminal A except it has
a slightly worse prognosis than luminal A breast cancer [85]. Within each type of breast
cancer mentioned above, there are various sub-types defined by their molecular profiles. Of
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particular interest due to its high prevalence among women in Canada is TNBC.
Over the past decade, researchers have been working to identify the molecular subtypes of
TNBC. In 2011, Lehmann et al. published a study that identified six molecular subtypes of
TNCB: basal-like 1 (BL1), basal-like 2 (BL2), immunomodulatory (IM), mesenchymal (M),
mesenchymal stem-like (MSL), and luminal androgen receptor (LAR) [68]. However, in 2016,
Lehmann updated their classification system because transcripts previously described in IM
samples were from infiltrating lymphocytes, and transcripts from MSL samples were actually
from tumor-associated stromal cells [69]. As as a result, the new classification system that
they propose contains only four of the above mentioned molecular subtypes of TNCB: BL1,
BL2, M, and LAR [69].
Interestingly, between the publishing of the Lehmann 2011 [68] and Lehmann 2016 [69]
manuscripts, three other research groups published different molecular classification systems
for TNBC [16, 59, 73]. Masuda et al. reported seven subtypes in 2013: BL1, BL2, M, IM,
MSL, LAR, and unstable (UNS) [73]. Burstein et al. 2015 reported four molecular subtypes
which they named LAR, mesenchymal (MES), basal-like immune-uppressed (BLIS), and
basal-like immune-activated (BLIA) [16]. In contrast, Jezequel et al. identified three molecu-
lar subtypes: LAR, and two different types of basal-like (one with high M2-like macrophages
and a low immune response, and the other with low M2-like macrophages and a high immune
response [59]).
There is an unsurmountable amount of evidence that strongly suggests that TNBC is
heterogeneous and made up of several different subtypes. Although there does not seem to
be a consensus on the molecular subtypes within the research community, it is reassuring
that most studies are identifying some of the same subtypes: basal-like, MES, and LAR.
Identifying molecular subtypes of breast cancer has broader applications for the cancer re-
search community. By expanding molecular subtyping analyses to multiple cancer types,
researchers can group cancers based on genetics rather than cell-of-origin. The hope is that
this novel method of classification will group cancers into types that are treatable by repur-
posing existing therapeutics and increase patient care.
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2.1.3 The tumor suppressor FBXW7
FBXW7 (F-box and WD repeat domain-containing 7) is the substrate recognition compo-
nent of the SCF (SKP/CUL1/F-Box) E3 ubiquitin ligase complex that has several aliases:
FBW7, AGO, CDC4, and SEL10 (Figure 2.1) [130]. FBXW7 has been classified as a tu-
mor suppressor [130], and studies have shown that loss of FBXW7 gene expression results
in chromosomal instability through deregulation of its protein substrates, including cyclin E
[111]. When conserved CDC4 phospho-degron motifs (CPDs) on target proteins are phos-
phorylated, FBXW7 binds to them and the protein substrate is targeted for ubituitination
through the SCF complex. Because the substrates of FBXW7 are involved with cell division,
cell growth, and cell differentiation, phosphorylation of these substrates by glycogen synthase
kinase 3 (GSK3) is highly regulated [26]. The proteins that FBXW7 interacts with include
several well known oncogenes including cyclin E, JUN, Notch, and MYC [130].
The FBXW7 gene is located on human chromosome 4q32, a location that is often deleted
in cancers [112]. Because FBXW7 is part of the SCF E3 ubiquitin ligase complex, in cancers
where it is deleted, its oncogenic substrates become excess in the cell. For this reason,
FBXW7 was proposed to function as a tumor suppressor [129]. It has also been shown that
FBXW7 is mutated in around 6% of cancer tumors but with a large amount of variation
between tumor types. For example, the cancer types most frequently mutated are T-cell
acute lymphoblastic leukaemia (T-ALL) and cholangiocarcinoma with 31% and 35% of cases
harbouring a mutation in FBXW7 respectively [1]. In contrast, prostate cancers has a 6%
mutation rate [63].
The FBXW7 protein contains an F-box protein interaction domain that interacts directly
with SKP1 (S-phase kinase associated protein 1) and is responsible for the recruitment of
ubiquitination substrates to the SCF [62]. It also contains eight WD40 repeats that are
used to interact with its phosphorylated protein substrates at the CPD domain [46], and
a D domain that is used for the dimerization of FBXW7 [129]. The third and fourth WD
repeat domains of FBXW7 contain 3 conserved arginine residues that interact with the
phosphorylated substrates, while the remaining repeats are responsible for substrate binding
[46, 86].
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Figure 2.1: A schematic diagram of the SCF protein complex reprinted with permis-
sion from Nature Reviews Genetics (Appendix C.1) [130].
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Given that FBXW7 is responsible for the degradation of several oncogenes, it is not
surprising that targeting FBXW7 and it’s substrates could be a viable approach to treating
cancers. Targeting FBXW7 directly is one option given that a large portion of tumors
maintain FBXW7 expression. However, in cancers where FBXW7 is lost, a better approach
might be to target the oncogenic substrates of FBXW7. This has already been achieved
for two substrates of FBXW7: in human T-ALL Notch has been targeted using γ-secretase
inhibitors, and in murine sarcomas, MYC has been targeted using γ-secretase inhibitors as
well [42, 57]. Another potential avenue for targeting cancers through loss of FBXW7 is to
evaluate SL interactions with FBXW7 and use those genes as potential drug targets. This
strategy would be particularly useful for cancers with low expression of FBXW7 since it’s
SL partners can be targeted with drugs on a patient by patient basis.
2.2 Yeast as a model organism
Model species are often extremely useful starting points for research. In the case of yeast,
there are several studies that support its utility and application to human research, especially
cancer research [11, 43, 75, 91, 92, 95, 97, 104]. Hartwell was the first to discover genes
involved in the yeast cell cycle [49, 50, 95]. These cell division cycle (CDC) genes in yeast
have been studied extensively in a human cancer context [8, 17, 71, 99], and mutations
in these genes in humans have been shown to be involved in cancer [95]. In addition to
having genes that are relevant to studying human cancer, yeast is also easily cultured in a
laboratory and has a relatively small genome [41]. Furthermore, there are currently many
research groups focusing on yeast resulting in large amounts of data that can be mined and
applied to human cancer research [11, 43, 75, 91, 92, 95, 97, 104].
2.2.1 Ortholog mapping
Prior to discussing the ways of mapping yeast genes to human genes, it is important to
identify and define the following key evolutionary terms: homologs, orthologs, and paralogs.
Homologs are genes with a common evolutionary origin but not necessarily the same function
and can be divided into orthologs and paralogs. Orthologs are genes with a common ancestor
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that are separated by speciation and have kept the same function over time. In contrast,
paralogs are genes with different functions in the same genome related by duplication. There
are two main ways that ortholog mapping is conducted in silico: sequence similarity (for
example using a BLAST-based approach (basic local alignment search tool) [56, 70, 109])
and a phylogeny-based approach [55, 96, 100, 141]. The BLAST-based approach involves
pairwise sequence comparison and is a fast approach for identifying potential orthologs. In
contrast, the phylogeny-based approaches compare gene trees to species trees to identify
gene duplication events and predict orthoogy. Furthermore, phylogeny-based approaches are
more time- and resource-intensive but are useful in identifying more fine-grained ortholog
relationships. InParanoid was built using a sequence similarity approach and has an easy-to-
use interface.
2.3 Synthetic lethality
There are many different genetic interactions that researchers can exploit in order to identify
potential genes that would act as drug targets for cancer therapeutics. Genetic interactions
are the phenomenon where two or more gene products interact with one another that results
in a deviation of the expected phenotype [78]. Two such genetic interactions are synthetic
lethality and synthetic dosage lethality. A SL interaction involves a pair of genes (geneA and
geneB) where inhibition of either geneA or geneB individually has no effect on cell viability,
but the inhibition of both geneA and geneB causes cell death. In contrast, a synthetic dosage
lethal (SDL) interaction involves a pair of genes (geneA and geneB) where over-expression of
either geneA or geneB individually has no effect on cell viability, but the inhibition of geneA
when geneB is over-expressed causes cell death (Figure 2.1). The concept of synthetic lethality
was first described in 1922 by Calvin Bridges [15]; however, recent applications to cancer
and the discovery of complex SL interactions (such as SL triples and quadruples [74]: SL
interactions where all three or four genes need to be down-regulated for the lethal phenotype)
are more recent applications of the concept. There are three proposed mechanisms of SL
interactions: (1) each gene is involved in parallel redundant cellular pathways, (2) genes are
members of distinct cellular pathways that generate the same product, and (3) the genes are
12
Figure 2.2: A schematic diagram of SL and SDL reprinted with permission from Cell
Press (Appendix C.2) [89]. (i) represents a schematic of SL and (ii) is a schematic
representation of SDL.
translated into different subunits of the same protein complex (Figure 2.2) [34].
Synthetic lethality has a wide array of applications in microbial, plant, animal, and hu-
man research. The most effective means of accurately identifying SL interactions is through
in vitro assays that knock down both genes and monitor cell survival. This is often done in
vitro and in vivo using CRISPR-Cas9 [102] or RNA interference [32]. Despite similar meth-
ods for identifying SL interactions, applications in microbes, plants, and animals (including
Drosophila melanogaster and Caenorhabditis elegans) are different from cancer applications
in humans. For example, in bacteria SL interactions have been evaluated to determine
essential plasticity (the SL interaction works as a backup mechanism, e.g. Cell Envelope
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Figure 2.3: A schematic diagram of mechanisms of SL reprinted with permission from
European Journal of Cancer (Appendix C.3) [34].
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Biosynthesis as an essential backup for Membrane Lipid Metabolism) and essential redun-
dancy (the SL interaction works as a parallel mechanism - shown by SL interactions affect
a single function or pathway e.g. apoptosis) in metabolic networks [44]. In other microbial
studies, SL interactions are used to identify gene functions in metabolic pathways [117], pre-
dict flux distribution and metabolic function for increased production of biofuels [51], analyze
metabolites in known pathogens [40], and discover antibiotic combinations [3]. Furthermore,
a large number of studies have focused on SL interactions in yeast, specifically Saccharomyces
cerevisiae. These studies include mining protein-protein interaction networks for SL interac-
tions [88], screening for genome instability [139], flux balance analysis (a mathematical model
for simulating metabolism) to identify SL interactions relevant to metabolic pathways [47],
identifying genes required for chromosomal segregation [77], identifying complex molecular
interactions through SL interactions in multi-protein complexes [65], gene function prediction
[138], and examining the total set of SL interactions in the yeast genome [22, 23, 84].
Although in vitro assays are important for validating SL interactions, they can be time-
consuming, expensive, and labour-intensive, especially if the genome of the organism being
studied is large in size. For example, studying SL interactions in vitro in human cancers
requires extensive cell line work and the generation of millions of double-mutant cell lines in
order to evaluate all possible SL interactions. Given approximately 20,000 genes in the human
genome, there are almost 200,000,000 genetic interactions in an exhaustive in vitro screen.
To that effect, identifying higher order SL triples or quadruples in vitro becomes increasingly
more expensive and time-consuming as the dimensionality of the problem increases [74]. As a
result, researchers are beginning to exploit SL interactions in model organisms (such as yeast
[22, 23, 84]) to identify promising SL candidate drug targets. These approaches are more time-
and cost-effective since they reduce the number of potential SL interactions to a feasible set
that can be evaluated in vitro in a reasonable amount of time. Additionally, computational
studies are working on developing predictive models for synthetic lethality that will serve as
a form of dimensional reduction, which means that in vitro resources can focus on validating
SL interactions that have already been computationally predicted [27, 58, 74, 105, 114].
Therefore, it is not surprising that there is an increased interest in computational approaches
to identifying SL interactions in humans that make use of previously identified SL interactions
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in model species.
2.4 Computational approaches for identifying SL inter-
actions
Often, if geneA is mutated, down-regulated, or not expressed in cancer and it is in a SL
interaction with geneB, then geneB becomes a potential target for novel or existing drugs.
This type of targeted drug-gene interaction can reduce the side effects of the drug, increase
the efficiency of treatment, and increase the comfort of the patient during treatment. It
can also prevent patients from being treated with drugs that will not be as effective for their
cancer, reducing the cost and length of patient treatment and potentially preventing negative
side effects like liver damage from excessive (or unnecessary) chemotherapy. Computational
approaches to synthetic lethality in cancer are increasing in popularity using existing cell
line gene expression data, patient survival and mutation data, and previously experimentally
validated SL interaction data from model organisms (e.g. yeast) [27, 58, 74, 94, 114].
Some programs are designed just for the purpose of identifying SL interactions in mi-
crobes, such as Fast-SL [94]. Fast-SL takes a linear programming approach to flux balance
analysis (FBA). FBA uses metabolic models to analyze fluxes in a network and analyzes
gene enrichment analysis, allowing for gene essentiality analysis and potential identification
of SL interactions [120]. Fast-SL was used to analyze Escherichia coli, Salmonella enterica
Typhimurium and Mycobacterium tuberculosis for SL interactions. It not only identified SL
gene deletions in all three species but also identified novel SL triples. This approach to SL
identification has applications in the identification of novel antibiotic targets and can help
researchers explore complex genetic interactions in pathogens.
In addition to studies that are focused solely on bacteria and yeast, there are also sev-
eral studies that identify SL interactions in yeast with the intention of applying them to
human cancer, or use existing experimentally validated yeast SL interactions to identify can-
cer relevant SL interactions. Using yeast and other species as model organisms for studying
SL interactions in humans can be extremely valuable, resource efficient, and help reduce
the sample size for in vitro and in vivo testing. For example, Meta-SL is a computational
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approach to identify SL gene pairs in yeast combining information from 17 genomic and pro-
teomic features with the results of several classification models [133]. Upon the identification
of SL interactions in yeast, ortholog mapping from yeast to humans revealed a set of cancer
relevant SL interactions to study further.
Other computational studies use previously identified yeast SL interactions to identify
potential SL interactions in human cancer [27]. Deshpande et al. use existing yeast SL
interaction data from The Cell Map [22], ortholog mapping from yeast to humans, and
cancer mutation data in order to identify potential cancer relevant SL interactions. This
study identified 1,522 SL interactions relevant to cancer and tested SL interactions between
SMARCB1 and PSMA4, and ASPSCR1 and PSMC2 as proof of concept. More than 500
SL interactions containing at least one gene that is known to be associated with cancer were
identified in this study.
In contrast, Srivas et al. identified a list of human cancer genes, mapped them to yeast or-
thologs and their SL interactions, and tested the resulting SL interactions in human cell lines
[114]. This strategy is arguably more cancer directed as it starts with a list of known human
tumor suppressor genes (TSG) and applies existing yeast genetic interaction data. Though
the results are highly relevant to human cancer, they are extremely focused on known TSGs
and there is the potential for the exclusion of SL interactions that might involve a previously
unidentified human TSG. Despite their differences, both of these research endeavours focus
on previously identified genes associated with cancer.
In contrast, the identification of SL interactions in humans without the use of a model
organism is complicated by the size of the genome, which greatly increases the number of
possible SL interactions. As a result, a number of specialized programs have been imple-
mented for the identification of SL interactions specifically in human cancer. One of the
more recent research efforts by Matlak and Szczurek [74] introduces SurvLRT, a program
that analyzes cancer patient data using a statistical likelihood ratio test in order to identify
SL gene pairs and triples in humans. SurvLRT is the first computational approach that
identifies biomarkers for SL drug therapy, and was successful in identifying TP53BP1 as
a biomarker for the well established PARP -BRCA1 SL gene pair. What’s more, SurvLRT
identified a novel biomarker for the same SL interaction that has a higher number of deletions
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in cancer patients than TP53BP1, opening new research avenues for personalized medicine
in cancer therapy.
Another computational pipeline for the identification of SL and SDL interactions in hu-
man cancer is DAISY (data mining synthetic lethality identification pipeline) [58]. DAISY
makes use of multiple cancer patient and cancer cell line datasets and uses three statistical
inference strategies to predict SL interactions in cancer. The first inference strategy, ge-
nomic survival of the fittest (SoF), analyzes somatic copy number alterations (SCNA) and
mutation profiles for gene pairs where gene B has higher SCNA values and where geneA
is inactive. The next strategy, shRNA-based functional examination, uses gene essentiality
profiles to determine if, for each gene pair, geneB has lower shRNA expression in samples
where geneA is inactive. Finally, DAISY evaluates pairwise gene co-expression using gene
expression profiles to identify gene pairs whose expression is positively correlated. Gene pairs
that are statistically significant in all three of the inference strategies are reported as positive
SL interactions in human cancer.
Unfortunately, because DAISY uses a small number of mutations and shRNA data from
existing cell lines, it misses all SL interactions that are false negatives in shRNA screens due
to a lack of representation in existing cancer cell lines or due to incomplete knockdown. To
counter these shortcomings, Sinha et al. [105] developed MiSL (mining synthetic lethals)
to identify cancer specific SL interactions in specific cancer types. The MiSL algorithm is
based on Boolean implications mined from pan-cancer datasets. Because MiSL takes into
account all types of mutations, compared to DAISY which only takes into account frame
shift and non-sense mutations, MiSL out performs DAISY by identifying several novel SL
interactions that DAISY can’t identify. This does not mean that MiSL is perfect; rather, it
shows that research is constantly being completed to improve computational approaches for
SL identification in humans.
Since these computational methods rely on the use of existing datasets, there is still a need
to validate their conclusions in vitro (and sometimes in vivo) to ensure that the computational
method is accurate. However, with an increasing number of SL interactions identified through
cell line testing and a database for synthetic lethal interactions (SynLethDB [45]), it is now
possible to validate in silico approaches by comparing the results to SL interactions that
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have been previously identified in the lab and by other SL computational approaches. This
may pose challenges though as a novel computational method of identifying SL interactions in
humans might have no SL interactions in common with previous research and the predicted SL
interactions have to be validated through in vitro and in vivo studies. However, results that
have overlap with existing computational methods can be partially validated by analyzing
those interactions. In vitro and in vivo studies can then provide additional support for the
interactions that overlap with existing studies.
Unfortunately, there only a few databases that contain human SL interaction data from
multiple studies. The most well known is the SynLethDB [45], which contains SL interac-
tions from large scale computational studies, SL interactions recovered from text mining,
and computationally derived SL interactions from the DECIPHER database [36]. Unfor-
tunately, there are errors in this database (see Results and Discussion), which result in a
loss of confidence in the text mining entries and reduction in the number of SL interactions
available. However, SynLethDB is a starting point for comparing known SL interactions to
those identified in novel computational studies.
This thesis combines previously identified yeast genetic interaction data with yeast-human
orthology data to develop a novel network of human SL interactions that can be computa-
tionally verified using existing studies. As mentioned earlier, Deshpande et al. [27] used
existing SL interaction data from yeast to identify SL interactions in human cancer (this
topic expanded on in section 6.1). The research described here is based on their approach;
however, updated databases and patient gene expression data from The Cancer Genome At-
las (TCGA) is used to generate a breast cancer specific set of SL interactions in humans.
Using this information in conjunction with SynLethDB entries, we show that the network of
predicted SL interactions in humans is not the result of random chance and further identify
32 druggable gene targets specific to breast cancer.
2.5 Data sources for computational studies
In order to use a computational approach to identify human SL interactions previous data
and experimental results were necessary to begin the analyses. The main sources of data for
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the work presented in this thesis were: The Cell Map [123], the TCGA database (https://
cancergenome.nih.gov/), SynLethDB [45], and the InParanoid database [109]. In addition
to these main data sources several additional data sources were used such as: cancerRXgene
database [136], the cancer cell line encyclopedia (CCLE) [7], the Ensembl database [141],
and the work of Deshpande et al. [27] in order to curate, compare and analyze the data in
this thesis.
2.5.1 The Cell Map
As previously discussed, yeast is a good model organism for studying cancer in humans
(Section 2.2). The starting dataset for the generation of the HYGIN network was The Cell
Map [123]. Cell Map is a current dataset of previously biologically validated yeast genetic
interactions that was last updated May 2016. The dataset covers close to 90% of yeast genes
and contains approximately 550,000 negative and 350,000 positive yeast genetic interactions.
In the Cell Map dataset, deletion query mutant strains were screened against deletion mutant
arrays in the search for genetic interactions. Interactions were scored based on an  value (a
score for genetic interactions1) and statistical significance. Using the data cut-off values for
P-value and  as described in the work by Deshpande et al. [27], a subset of the Cell Map
data was used to generate the HYGIN network.
2.5.2 InParanoid
Orthologous mapping of yeast to human genes used the InParanoid database of orthologs
[109]. As mentioned previously, the InParanoid database contains 273 species, 37,128 species
pairs, and 2,999,062 orthologous proteins including 2,041 orthologs between yeast and humans
[109]. InParanoid uses sequence similarity implemented through a BLAST-based approach
to ortholog mapping and accounts for one-to-one and one-to-many orthologs between pairs
of species. InParanoid uses bootstrap confidence values to assign a confidence score that the
seed used for the comparison and it’s ortholog are true orthologs. InParanoid version 8 is the
1The specific details for how  was calculated were not provided in the original manuscript, nor were
explicit details given in the original Science paper [122].
20
most current version [109], and it is updated regularly to include new genetic information for
identifying orthologs.
2.5.3 The synthetic lethal database
SynLethDB is a curated database that contains SL gene pairs from other databases, biochem-
ical results, text mining, and computational predictions [45]. In addition to 19,952 human SL
interactions, the SynLethDB contains SL interactions for Saccharomyces cerevisiae (13,241),
Drosophila melanogaster (423), Mus musculus (366), and Caenorhabditis elegans (107). Two
of the major contributors to the human SL interactions in the SynLethDB are a computa-
tional study, DAISY (discussed in Section 2.3) [58], and SL interactions that were identified
through an analysis of the DECIPHER database [36]. The remaining major contributors to
the SynLethDB are other smaller in vitro analyses and SL interactions identified through
a text-mining algorithm. The text mining approach that Gou et al. used for SynLethDB
involved three major steps: search, train, and extract. During the search step, the titles
of the articles in the PubMed database were searched for the terms “synthetic lethal” and
“synthetic lethality”. The abstracts of the 331 articles that were identified to contain these
terms in their titles were used in to train the literature ranking tool, MedlineRanker [37].
MedlineRanker uses a defined training set (e.g. the previously mentioned 331 abstracts)
to rank the literature in a database according to how relevant they are to synthetic lethal-
ity. Gou et al. chose to use the top 1,000 articles from the past 10 years in their search
for SL interactions from previous literature. The third step in their text mining procedure
was to use PESCADOR (Platform for Exploration of Significant Concepts AssociateD to
co-Occurrence Relationships) [6], an online tool for identifying biointeractions from articles
in the PubMed database. Based on the information from MedlineRanker, PESCADOR used
keywords to identify SL interactions in the literature. Although the text mining portion of
the SynLethDB contained several errors (see Section 5.2 for greater detail and examples),
text mining approaches are a valuable means of populating databases and consolidating in-
formation for in silico studies provided that checks and balances are in place. The authors
report that they will address the errors in the upcoming version of the database.
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2.5.4 The cancer genome atlas
The cancer genome atlas is currently one of the most up-to-date comprehensive publicly
available cancer genetics databases (https://cancergenome.nih.gov/). In addition to can-
cer gene expression data for more than 10,000 cancer samples across 33 cancer types, the
TCGA also contains mutation data, patient data, and raw sequencing data. Additionally,
the TCGA contains non-cancerous gene expression data for some cancer patients, including
114 normal breast tissue samples from 114 breast cancer patients. This paired data, i.e. gene
expression data from normal tissue and cancerous tissue from the same patient, is extremely
valuable for researchers. Specifically, it gives researchers the ability to evaluate differential
gene expression in cancer versus normal tissue while accounting for baseline gene expression
in individual patients.
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Chapter 3
Research Hypothesis
Although the principle of using bioinformatics techniques for the identification of SL
interactions in silico is not new, there are ways that we can improve upon previous techniques
and approaches to better identify SL interactions in breast cancer. With a constant increase
in the amount of patient genomic data and an ever-increasing number of cancer cell lines (and
genomic data for these cell lines), novel practical approaches are needed for the analysis of this
data. Furthermore, there are also a number of studies that have started with experimentally
validated SL interactions in non-human model organisms and used this data as a spring
board for the identification of SL interactions in human cancer. This thesis describes an
improved approach using yeast orthologs to develop a humanized genetic interaction network
in a cancer independent context.
This thesis used yeast genetic interaction data from The Cell Map [23] and cancer gene
expression data from the TCGA to identify breast cancer specific SL interactions. We hy-
pothesize that the creation of an improved and updated humanized yeast genetic interaction
network based on yeast-human orthologs and the application of breast cancer gene expression
data will allow us to identify genes for targeted breast cancer therapeutics. The pursuit of
this hypothesis was broken down into the following goals:
1. Curate the existing yeast genetic interaction network from The Cell Map, and convert
it to a humanized genetic interaction network that uses gene identifiers that can stand
the test of time with minimal changes.
2. Identify the set of genes that are down-regulated in breast cancer patients using TCGA
data.
3. Map the set of down-regulated genes onto the humanized yeast genetic interaction
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network to generate a breast cancer specific subnetwork.
4. Identify genes that have SL interactions with multiple cancer related genes that are
down-regulated in breast cancer.
5. Identify potential novel drugs for target genes using the drug-gene interaction database.
The goal of this project is to generate a humanized yeast genetic interaction network
(HYGIN) based on human orthologs in yeast in a cancer independent context, apply cancer
gene expression data, and identify novel SL gene pairs for targeted breast cancer therapeutics.
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Chapter 4
Data and Methodology
Using yeast genetic interaction data as the basis for identifying SL interactions in humans
is not a novel concept. Previously, the work of Deshpande et al. used yeast genetic interaction
data to generate a cancer-independent human SL interaction network [27]. However, their
network used all yeast-human orthologs including instances of one-to-many and many-to-
many mapping. Using an updated version of the yeast interaction dataset [23], and working to
improve on the strategy of Deshpande et al., this thesis generates a stringent humanized yeast
genetic interaction network that uses strict one-to-one yeast-human ortholog mapping. We
then use breast cancer data from the TCGA and generate a breast cancer specific subnetwork
that contains potential gene targets for breast cancer therapeutics.
4.1 Generating the humanized genetic interaction net-
work
In order to generate HYGIN, experimentally validated yeast interactions from the May 2016
release of The Cell Map [23] were used. The yeast network contains quantitative genetic
interactions for all gene pairs in Saccharomyces cerevisiae and is the result of double mutant
arrays conducted in yeast that represent nearly all of the SL interactions in the yeast genome.
The yeast interaction data contains approximately 550,000 negative genetic interactions
(SL interactions) between approximately 90% of the genes in the yeast genome [23]. In order
to generate a humanized network, the yeast network was translated in three stages: yeast
gene name to yeast protein, yeast protein to human orthologous protein, and finally human
protein to human gene name. The UniProt database [2] was used for the first and last stages
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and InParanoid Version 8.0 [109], an online tool for identifying orthologs between two species,
was used to identify the human orthologs of the yeast proteins in stage two. Strict one-to-one
mapping with InParanoid was used for the network to prevent ambiguities in the translation
process (Supplementary Table B.1).
For example, The Cell Map contains the synthetic lethal interaction between the yeast
genes RPN1 and MET30. The names of these two genes were converted to yeast protein
accession numbers (P38764 and P39014 respectively). InParanoid ortholog mapping then
mapped the yeast protein accession numbers to human protein accession numbers (Q13200
and Q969H0 respectively). Finally, the human protein accession numbers were mapped to
the corresponding human genes PSMD2 and FBXW7, and a SL interaction between these
genes was added to the HYGIN network. Supplementary Table B.2 lists tall the interactions
in HYGIN.
Performing the mapping and filtering steps is tedious and error prone. Therefore the
process of generating HYGIN was automated and performed computationally using a combi-
nation of bash (UNIX shell) and Python scripts. The network information was imported into
Cytoscape [103] for visualization and analysis. The resulting network has 1,009 nodes (hu-
man genes) and 10,419 edges (proposed SL interactions between human genes). A summary
of this process can be found in Figure 4.1.
4.2 Creating the breast cancer specific subnetwork
HYGIN was developed in a cancer independent manner in order to avoid certain biases
such as starting with known oncogenes or TSGs, or limiting yeast ortholog mapping to only
known cancer associated genes in humans. As a result, HYGIN is disease independent and
the SL interactions in the network could be used for multiple different studies. However, our
research hypothesis involved identifying SL interactions that are relevant to breast cancer.
As a result, breast cancer data needed to be incorporated into HYGIN in order to identify
potential gene targets for breast cancer therapeutics. This was accomplished through the
integration of TCGA breast cancer data with HYGIN and the generation of a breast cancer
specific subnetwork. The TCGA contains gene expression data for both normal (114 samples)
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The Cell Map: yeast 
genetic interaction data:
~550,000 negative (SL) 
interactions 
Humanized genetic 
interaction network:
1,009 nodes
10,419 edges
TCGA breast cancer 
patient gene expression 
data for 114 patients with 
cancer and non-cancer 
tissue
1,745 genes down-
regulated in breast cancer 
at 2-fold or more cut-off 
and P-value < 0.05
Breast cancer specific 
subnetwork:
130 (15 + 115) nodes
130 edges
Figure 4.1: Flow diagram showing the flow of data and method used to generate the
breast cancer specific subnetwork.
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and cancerous (1,104 samples) tissue.
Some studies use all available data as a means of reaching statistically significant results,
or as a means of completing an exhaustive analysis [58, 106], for example, using pooled
normal tissue data and comparing it to pooled cancers tissue data as a means of statistically
evaluating changes in gene expression. However, we used a more stringent methodology and
only analyzed TCGA patient data for which there was gene expression data for both breast
cancer tissue and normal breast tissue from the same patient. This increases the confidence
in determining gene up- and down-regulation as it helps eliminate false positive results that
occur due to differences in basal gene expression between individuals. By comparing up- and
down-regulation of genes between two like-tissue samples from the same patient, changes
in expression are more reliable than pooling cancer samples and comparing them to pooled
normal samples. Although this strategy is very stringent, it is also one of the strengths of
our gene expression analysis.
Gene expression data was downloaded from the TCGA database (https://cancergenome.
nih.gov/). Gene expression data for cancerous tissue and normal tissue in the same patient
was available for 114 patients: level-3 HiSeq RSEM gene-normalized RNA-seq data was ob-
tained for 1,104 cancerous and 114 normal samples for 20,530 genes. However, some genes
had zero values for one or more patients as a result of either there being no transcripts se-
quenced, or transcripts missing for a particular gene. Consequently, different methods were
attempted to resolve these issues, some of which were not included in the final analysis.
4.2.1 Initial analysis
The initial data analysis workflow for identifying genes down-regulated in breast cancer re-
moved genes with some (84 or more) expression values of zero. The TCGA dataset for
breast cancer contains normal and cancerous gene expression data for 20,531 genes in both
cancerous and normal tissue across 114 patients. Since the TCGA gene expression datasets
for breast cancer are incomplete (i.e. there are numerous genes that do not have 114 ex-
pression values for all patients), there were instances of genes with zero values for either
cancerous and/or normal samples certain from patients. There were 6,575 genes that had
gene expression values of zero for between 1 and 114 patients from cancerous and/or normal
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tissue datasets. As a preliminary step, approximately 1,000 genes with zero values for all
114 patients were removed from the analysis entirely due to the lack of data. However, some
genes still had zero values for the majority of patients, which would invalidate down-stream
statistical analyses. As a result, in order to have sufficient data to complete valid statistical
tests (whether parametric or non-parametric), a minimum of 30 non-zero gene expression
values were required for each gene. Therefore, 18,654 genes out of 20,531 genes total with at
least 30 non-zero values were identified for further analysis in the initial analysis method.
When using statistics to analyze large datasets, it is important to use an appropriate test
that reflects the normality of the data. The Shapiro-Wilk test for normality tests datasets to
determine whether or not they follow a normal distribution. In order to maintain stringency
in our analysis, the Shapiro-Wilk test was conducted on the expression values of the 18,654
genes that had at least 30 non-zero values. The results of this test showed that the gene
expression data did not have a normal distribution even though the sample size would have
been large enough to make the assumption of normality [28]. Therefore, a non-parametric
test was used to analyze this data as it is a more appropriate statistical method for the data.
In spite of the above method of maintaining some zero values in the dataset, by evaluating
samples with 30 to 114 paired values per gene (where there is a non-zero value for both cancer
and normal tissue), there was the potential for misrepresentation in some genes compared
to others, which could lead to potential false positive results. For example, geneA could be
found to be down-regulated in breast cancer with a sample size of 30, but in reality if we had
genetic data from 114 patients we would see no statistical change in gene expression. As a
result, this workflow was not used to generate the breast cancer specific subnetwork.
4.2.2 Final analysis
To improve upon the initial analysis, and to ensure that the results moving forward were
statistically sound, any gene for which there was one or more expression value of zero in
either cancerous or normal tissue were removed in the final version of the analysis. For
example, if there is a zero value in the cancer data set for geneA, then that gene is removed
from the analysis regardless of whether it has a zero value in the dataset for normal tissue.
This filtering procedure resulted in analyzing data for 13,938 genes out of the 20,531 genes
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in the TCGA breast cancer dataset.
Once zero values had been accounted for and dealt with accordingly, the Shapiro-Wilk
test was conducted again on the remaining 13,938 genes. The Shapiro-Wilk test showed that
although more than 30 samples were present for each gene, the expression values were not
normal and a non-parametric statistical test was required. The Wilcoxon signed-rank test
was selected as the non-parametric statistical test for the paired data to determine if the
median gene expression between the cancer sample and the normal sample was statistically
different (P < 0.05). Since greater numbers of statistical inferences made from a dataset
increases the chances of an error in any of those inferences, it was imperative to account for
multiple hypotheses.
4.2.3 Multiple hypothesis testing
Two types of multiple hypothesis corrections were considered for the data analysis, the Bon-
ferroni correction and the Benjamini-Hochberg procedure. The Bonferroni correction corrects
for family-wise error rate (FWER), whereas the Benjamini-Hochberg procedure corrects for
false discovery rate (FDR)[118].
FWER represents the probability of making a Type I error (false discovery) when testing
multiple hypotheses using the same data and reduces the probability of making a type I error
with respect to the results returned as positive compared to the original P-value. In contrast,
FDR conceptualizes the rate of Type I errors when conducting multiple comparisons. The
Bonferroni correction is one of the most strict corrections for multiple hypotheses. Adjusted
P-values are calculated by dividing each critical value by the total number of hypotheses (n)
being tested (e.g. P-value/n). This procedure affects all critical values equally, which can
lead to false negative results because it is so strict. Also the Bonferroni corrections results in
a group of hypotheses where α (the allowable percentage of false positive results e.g. 0.05)
results are expected to be false positives. Furthermore, the more tests (or the larger n), the
greater the effect the Bonferroni correction will have on P-values. In contrast, the Benjamini-
Hochberg procedure affects P-values based on their rank (e.g. (P-value’s rank/n) * α) where
α is the probability of making a Type I error). FDR procedures, such as the Benjamini-
Hochberg procedure, are less stringent when it comes to false positives in the data; however,
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they have greater statistical power. As a result, for our Wilcoxon signed-rank test on the
TCGA data we used the Benjamini-Hochberg procedure, choosing increased statistical power
at the cost of potential false positives in the results. In contrast, the Bonferroni correction
was used for the Shapiro-Wilk tests for normality on the cancer and non-cancer datasets.
It was selected because it is a more stringent statistical test and we wanted to ensure that
normality was not being incorrectly assumed.
4.2.4 Determining gene down-regulation in breast cancer
In order to determine if a gene was down-regulated in breast cancer, two analyses had to
converge: the Wilcoxon signed-rank test results and the evaluation of gene expression ratio
in breast cancer. To determine the fold change of gene expression between the cancerous
and normal tissue, the ratio of gene expression was calculated (cancer/non-cancer) and the
log-base-2 of the ratio was used as the fold change in gene expression in breast cancer. Once
the fold change was calculated and Wilcoxon signed-rank test P-values were corrected for
multiple hypotheses, a cut-off value was needed to determine which genes were statistically
down-regulated in breast cancer.
We evaluated several potential cut-off values: 2-fold, 3-fold, 4-fold, 5-fold, 8-fold, and 16-
fold representing biological significance and one standard deviation representing statistical
significance. Though all of these cut-off values are technically valid, it was appropriate to
select the cut-off value that most accurately addresses the following question: which genes
are down-regulated in breast cancer tissue compared to normal tissue? Since we are asking
a biological question, a cut-off that represents an accurate biological significance threshold
should be used. As the fold change increases the results become more stringent and the
number of significant genes decreases. Biologically a higher fold change means that genes
have a greater change in expression when comparing cancerous to normal tissue. However,
the aim was to identify genes that are down-regulated, not genes that have large differential
expression in breast cancer. As a result, a lower fold-change threshold makes more biological
sense. Since a 2-fold cut-off represents instances where a gene in breast cancer has half of
the expression observed in healthy breast tissue, it was determined that this cut-off was
an accurate representation of the biological question. Consequently, genes that were down-
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regulated at a 2-fold or more cut-off in breast cancer and had a P-value (after adjustment)
< 0.05 were considered to be down-regulated in breast cancer.
4.2.5 Generating the breast cancer specific subnetwork
To give the SL interactions in HYGIN context in cancer, the results from analyzing the TCGA
breast cancer data were used to generate a breast cancer specific subnetwork of HYGIN. The
breast cancer subnetwork was generated by extracting the genes that were down-regulated
in breast cancer and all of their SL interactions from HYGIN. This subnetwork contains the
potential 130 SL interactions (edges) that are specific to breast cancer between 130 genes
(nodes) total; 15 genes that are down-regulated in breast cancer and 115 genes that have SL
interactions with them.
4.3 Validating HYGIN
HYGIN was validated in silico using the Synthetic Lethal Database (SynLethDB; July 12,
2017) [45] and a series of random networks. The SL interactions in the SynLethDB are
a combination of computationally predicted SL interactions, and SL interactions that have
been identified through large- or small-scale in vitro assays. Unfortunately, the text mining
algorithm for SynLethDB did not accurately identify SL interactions from the literature. As a
result they were all excluded from our validation procedure. Using the remaining information
in the database, we identified 11 SL interactions from HYGIN that have been identified by
previous studies. Eight of these interactions were computationally identified by DAISY [58],
and 3 were identified by SynLethDB through analysis of data in DECIPHER [36].
To determine if the 11 interactions identified by previous studies were statistically signifi-
cant or if they were the result of random chance, we generated 100,000 iterations of a random
network that mimics the original yeast interaction network. By generating multiple random
networks we can calculate the number of times that there were 11 or more SL interactions
in common with HYGIN that were the result of random chance. The random networks con-
tained the same number of nodes as there were yeast genes (5,587) and the same number of
edges as there were yeast SL interactions (132,312) in the yeast SL interaction network. Al-
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though there were approximately 550,000 negative genetic interactions in The Cell Map data,
only statistically significant entries were used for the generation of HYGIN and subsequent
analyses (P < 0.05 and  < −0.2, where  is the genetic interaction score used by Costanzo
et al. [23]). They were converted to a humanized genetic interaction network using the same
procedure as for HYGIN, and evaluated for SL interactions in common with the SynLethDB.
Random networks and comparison were completed using the Python library NetworkX.
4.4 Verifying one-to-one ortholog mapping of FBXW7
FBXW7 was selected as a target of interest for future analysis not only because it is a known
tumor suppressor, but because it is highly connected in the breast cancer subnetwork. With
32 potential SL interactions that can be exploited as therapeutic options, FBXW7 is an
ideal candidate for further testing in silico, in vitro, and in vivo. Since one of the major
motivations for using one-to-one yeast-human ortholog mapping was the lack thereof in the
previous work by Deshpande et al., it was important to verify the one-to-one mapping for the
gene of interest. To confirm that there were no additional yeast-human orthologs of FBXW7,
the InParanoid database [109] was searched twice: the human genome was searched for the
protein MET30 (the yeast protein that is orthologous to FBXW7 in humans) to ensure that
there was only one ortholog for the yeast MET30 protein, and for CDC4 (a common synonym
for FBXW7 in humans) to ensure that there were no additional orthologs for FBXW7 in the
database under its alias CDC4.
4.5 Gene expression in other cancers
A recent study showed that on average 43% of cancers from a specific tissue type were more
similar to tumors from a different anatomical site than they were to tumors of the same
tissue of origin [24]. Although generally cancer is diagnosed and treated based on the tissue
or origin, there is more and more evidence that supports the theory that genetically cancers
from different tissues can be more alike than not [53, 61]. As a result, the 15 genes that were
in HYGIN and identified to be down-regulated in breast cancer were also analyzed in the
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24 types of cancer in the TCGA database. For each of these 24 cancer types, pooled gene
expression for cancer tissue was compared to pooled gene expression for normal tissue. Since
we were evaluating these cancers for down-regulation, only cancer types where more than 7
of the 15 genes had lower expression in cancer than in normal tissue were reported.
4.6 Drug data analysis
In an attempt to validate the SL interactions of FBXW7 in silico we used cancer cell line drug
sensitivity data and cancer cell line gene expression data. We performed an in silico drug
sensitivity assay using data from the cancerRXgene database which contains drug response
data for many cell lines [137]. Using cell line gene expression data all cell lines were evaluated
and divided into two groups: those with high FBW7 expression, and those with low FBXW7
expression. The rational was that cell lines with low FBXW7 gene expression that are
susceptible to a drug provide support that the given drug is a potential therapeutic for
targeting the SL partners of FBXW7. In order to show this, the IC50 values for each
group (high FBXW7 and low FBXW7) were used to generate a P-value (Mann-Whitney U
test). The survival percentage data from the cancerRXgene database for each of 265 drugs
at different concentrations was the basis for the dose-response curves. Out of 265 drugs,
three were selected for further analysis based on the difference in susceptibility between
the FBXW7 high and FBXW7 low cell lines: Cabozantinib (P-value = 0.033), Selumetinib
(P-value = 0.006), and NSC-207895 (P-value = 0.099).
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Chapter 5
Results
5.1 Construction of HYGIN predicted 10,419 potential
SL interactions in humans for 1,009 human genes
Previously, a yeast genetic interaction network, The Cell Map, was described [23]. Using
this information and a strict one-to-one ortholog mapping from yeast to human from In-
Paranoid [109] (Supplementary Table B.1), we generated a refined network: HYGIN (Figure
5.1). HYGIN contains all of the yeast orthologs of human genes and their predicted SL
interactions. Of the approximate 550,000 negative genetic interactions in yeast (Costanzo
2016; http://thecellmap.org/costanzo2016/, updated May 2016) we evaluated only sta-
tistically significant interactions with a P-value < 0.05 that were also strong negative inter-
actions where  < −0.2. Using InParanoid mapping from yeast to human, the yeast network
was reduced to statistically significant strong negative interactions that exist between the hu-
man orthologs of these yeast genes. The resultant HYGIN contains 1,009 genes and 10,419
proposed SL interactions (Supplementary Table B.2). Topology of this network combined
with our Gene Ontology (GO) Slim terms (Supplementary Table B.3) shows dense clustering
between genes involved in DNA damage and repair pathways and cell cycle regulators; or
RNA processing and ribosome biogenesis and translation components, suggesting we have
recovered meaningful humanized genetic interactions (Figure 5.1, Figure A.1). Since there
are only 1,266 yeast genes that map to exactly one human ortholog, it is not surprising that
the total number of human genes in the humanized network is less than that in the starting
yeast network, as only a fraction of these genes have human orthologs.
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Figure 5.1: HYGIN network. Nodes are clustered around the perimeter of the network and coloured by GO slim terms
which represent different biological processes. Each node represents one of the 1,009 human genes in the network. An
edge between two genes represents a SL interaction translated from yeast. Denser areas of the network indicate a higher
number of SL interactions between GO slim terms, while sparser areas of the network indicate fewer interactions between
GO slims. Note that some areas of the network are sparser due to fewer genes representing a specified GO slim term and
other areas of the network are over-represented increasing the number of edges in the network.
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5.2 Validating the HYGIN network using SynLethDB
In order to validate the interactions in the HYGIN network in silico, the SL interactions
in HYGIN were compared to the SynLethDB. The SL interactions in the SynLethDB are
a combination of computationally predicted SL interactions, and SL interactions that have
been identified through large or small-scale in vitro assays. Unfortunately, the text mining
algorithm for SynLethDB did not accurately identify SL interactions from the literature. As a
result they were all excluded from the validation of HYGIN. Of note, 6 SL entries in the Syn-
LethDB identified through text mining were found to have some error or discrepancy (Table
5.1). Some of the errors were minor. For example, an SL interaction between PSMD14 and
PSMD4 was in the SynLethDB despite the SL interaction being between RPN11 and RPN10
in the source manuscript. (RPN11 and RPN10 are synonyms for PSMD14 and PSMD4, re-
spectively.) Other errors were major. A manuscript identifying yeast SL interactions was
included in the SynLethDB and said to have human SL interactions; a manuscript that did
not contain the words “synthetic”, “lethal”, or POLD1 was included in the SynLethDB and
recorded as having two SL interactions between POLD1 and other genes; and most notably,
a manuscript whose only reference to SL was in one of the references was identified by the
SynLethDB to have 6 SL interactions. The data regarding these errors has been summarized
and included as a table (Table 5.1), and the authors of the database were informed about
the discrepancies and were eager to address them in the next version of SynLethDB.
Using the information in the database (except for text mining entries), we identified 11
SL interactions from HYGIN that have been identified by previous studies. Eight of these
interactions have been computationally identified by DAISY [58], and 3 were identified by
SynLethDB through analysis of data in DECIPHER [36]. The genes involved in these 11
interactions are summarized in Table 5.2. Since the number of SL interactions in common
was low we wanted to test to see if these interactions could be the result of random chance
or not. To do this we performed 100,000 iterations of the yeast-human ortholog mapping
process starting with a random network that mimics the original yeast interaction network.
It was found that there were 0 iterations that resulted in a humanized network having 11 or
more SL interactions in common with the SynLethDB. However, there were random networks
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PubMed ID Description of error
SL interactions in 
SynLethDB
23651857
LSM2 does not appear in the manuscript and there is no direct 
mention of synthetic lethal interactions in the manuscript 
itself. The only reference to synthetic lethal interactions is 
one of the references: Luo J, Emanuele MJ, Li D, Creighton 
CJ, A1:G7 MR, Westbrook TF, Wong KK, Elledge SJ 2009. 
A genome-wide RNAi screen identifies multiple synthetic 
lethal interactions with the Ras oncogene. Cell 137: 835–848
GSC LSM2                  
LSM2 MYC                   
LSM2 PHF5A                  
GSC MYC                     
GSC PHF5A                   
MYC PHF5A
16135799
FEN1 and FBXO18 do not appear in the manuscript. The 
manuscript is about yeast synthetic lethal interactions, not 
human synthetic lethal interaction. 
FBXO18 RAD51  
FBXO18 FEN1  
FEN1 RAD51
25139395
POLD1 is not mentioned in the manuscript. Neither are the 
terms "Synthetic" nor "Lethal".
POLD1 RAD51 
RAD51 RELA 
POLD1 RELA
23980094
The only two valid synthetic lethal interactions in this 
manuscript are ASPSCR1 and PSMC2, and SMARCB1 and 
PSMA4. The other interactions for this manuscript listed in 
the database are just every possible combination of these two 
genes. 
ASPSCR1 PSMA4 
ASPSCR1 PSMC2 
PSMA4 PSMC2 
PSMA4 SMARCB1 
PSMC2 SMARCB1 
ASPSCR1 SMARCB1
20941496
Valid SL interaction, although synonyms of the genes in the 
source manuscript are used: PSMD14 is a synonym for 
RPN11, and PSMD4 is a synonym for RPN10 where neither 
PSMD14 nor PSMD4 appear in the manuscript.
PSMD14 PSMD4
25334017
This manuscript is about embryonic lethality, not synthetic 
lethality. CDC45 only appears in the manuscript 3 times 
(once in the abstract and twice in the introduction), and is not 
described in the manuscript as involved in a synthetic lethal 
interaction.
CDC45 GINS1 
CDC45 GINS3 
GINS1 GINS3 
GINS3 TAP2       
CDC45 GINS4       
GINS3 GINS4       
GINS4 TAP2       
CDC45 TAP2       
GINS1 TAP2       
GINS1 GINS4
Table 5.1: List of SL interactions identified in the SynLethDB that were found to
have errors. “PubMed ID” is the PubMed accession number of the source manuscript.
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GeneA GeneB PubMedID Source
KRI1 NOP56 25171417 DAISY
NCAPG NCAPH 25171417 DAISY
TAF5 YEATS4 25171417 DAISY
DLD SUCLA2 25171417 DAISY
CHAF1B FEN1 25171417 DAISY
KIFC1 NCAPD2 25171417 DAISY
MCM6 WDHD1 25171417 DAISY
LIG1 RAD51 25171417 DAISY
GTF2H1 POLE 2667985 DECIPHER
PMS2 POLD1 2667985 DECIPHER
POLD1 POLE 2667985 DECIPHER
Table 5.2: List of SL interactions identified in HYGIN and the SynLethDB.
Table 5.3: A list of the number of edges in common between the SynLethDB and the
100,000 random networks used for validation. The number of edges column represents
the number of edges in common between the two networks, and the number of networks
column represents the fraction of random networks (out of 100,000) that contain that
number of edges in common with the SynLethDB.
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that had between 1 and 10 edges in common with the SynLethDB (Table 5.3). As a result,
we can say with high confidence (P-value < 0.00001) that identifying these 11 interactions in
common between HYGIN and the SynLethDB were not the result of random chance. Using
this approach, we were able to show that the interactions in the network are statistically
significant when compared to random networks.
5.3 Identification of down-regulated genes in breast can-
cer and building a breast cancer-specific SL inter-
action network
To make HYGIN more applicable for human cancer therapeutics, we focused on breast cancer
and developed a breast cancer specific subnetwork. Exploiting any yeast SL interaction
may not be beneficial if neither of the genes is altered in cancers. As a result, in order
to identify those interactions in HYGIN that are relevant to breast cancer, we used TCGA
data (https://tcga-data.nci.nih.gov/tcga/) to identify genes that are down-regulated
in breast cancer. Although there are gene expression data for over 1,000 breast cancer
patients available in TCGA, because gene expression is a relative measurement, we chose
to use only those tumor samples that had matching normal gene expression data. That
is, we used data only from patients where gene expression results were available for both
cancer and normal tissue. This stringent approach was followed to eliminate those genes
that are down-regulated in cancer, but whose expression in normal tissue is also low. In
order to determine if genes were statistically down-regulated in breast cancer, we first had
to determine which statistical test to use. The Shapiro-Wilk test for normality was used
on the initial data and results showed that values from 80% of genes in the cancer dataset
had normal distributions, compared to 56% of the genes in the dataset for normal tissue.
These results indicated that despite being able to assume that the data followed a normal
distribution [28], a non-parametric test was more appropriate for analyzing the data.
Our stringent procedure removed genes with any zero values for calculating gene up- and
down-regulation in breast cancer. This was a very stringent method of analyzing the data,
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and resulted in the removal of 6,593 genes from the initial dataset of 20,531 genes. The
resulting 13,938 genes had non-zero values for both the cancerous and normal datasets for all
114 patients. Although this stringent cut-off potentially removed genes that are statistically
down-regulated in breast cancer, it ensured a consistent sample size for all genes and reduced
the potential for false positive results. Given the change in dataset, the Shapiro-Wilk test for
normality was run again: 75% of expression values for cancer genes were normally distributed,
compared to 46% of normal genes. Therefore, to be consistent across all data, the Wilcoxon
signed-rank test was used. It determined statistical differences in the median gene expression
values for each gene between the cancer and normal tissue.
For each patient, gene expression data for cancerous and normal tissue was compared to
generate a log-2 ratio of cancerous to normal gene expression. By applying a 2-fold cut-off
and using genes with statistically different medians (P-value after adjustment < 0.05), 1,745
genes were identified to be down-regulated in breast cancer (Figure 5.2, Supplementary Table
B.4). Of these 1,745 genes that are statistically down-regulated in breast cancer, 181 were
previously identified in the tumor suppressor gene database (TSG; https://bioinfo.uth.
edu/TSGene/) as potential tumor suppressors.
The 1,745 genes that were statistically down-regulated in breast cancer were compared
to the HYGIN network, and it was found that 15 genes were in both datasets. These 15
genes included some of the well-established tumor suppressors like CAT [35] and FBXW7
[18]. The breast cancer specific subnetwork was generated using these 15 down-regulated
genes and the 115 genes that they have SL interactions with for a total of 130 genes (Figure
5.3, Supplementary Table B.5). The 115 genes are themselves not down-regulated in breast
cancer. By targeting the SL partners of the 15 genes that are already down-regulated in
breast cancer, novel targeted therapeutics can be developed to provide treatment options for
patients. A flow diagram of the methods used to analyze the breast cancer data and generate
the breast cancer specific subnetwork is depicted in Figure 4.1. An interesting note is that
these 15 genes were also found to be statistically down-regulated in breast cancer when all
cancer samples were pooled and compared to all non-cancerous samples (Figure 5.4, Figure
A.5, Figure A.6, Figure A.7).
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Figure 5.2: Volcano plot of the average change of expression per gene expressed as
log(2)[cancer/normal] plotted against the log(10) of the adjusted Wilcoxon P-value.
Dots in red represent genes that have an average 2-fold or more decrease in expression.
Back dots represent the 15 genes that are also in the HYGIN network.
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Figure 5.3: Visualization of the breast cancer specific subnetwork generated using 15 genes in HYGIN that were found
to be down-regulated in breast cancer (blue circles) and their corresponding SL gene pairs. Edges represent proposed SL
interactions between genes, and green nodes represent SL partners of the 15 genes.
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5.4 Synthetic lethal interactions of FBXW7 and their
validation
Having identified FBXW7 as a candidate gene worth exploring further, its yeast ortholog
and expression in other cancers was investigated. The yeast gene MET30 is an F-box protein
containing five copies of the WD40 motif and is known to control cell cycle function as part
of a E3 ubiquitin ligase complex [119]. According to InParanoid, FBXW7 is the human
ortholog of MET30 that shares similar roles in humans [109] (Figure A.2) In fact, FBXW7
is a well-known tumor suppressor that functions as a substrate-recognition protein within
a SCF (SKP/CUL1/F-Box) E3 complex ubiquitin ligase complex, which targets numerous
proteins for ubiquitin-mediated proteasomal degradation [130]. FBXW7 is down-regulated
not only in breast cancer, but also in 12 other cancers including colon, liver, lung, and prostate
cancers (Figure 5.4, Figure A.3). However, FBXW7 is also up-regulated in 6 other cancers
including three types of kidney cancer, lung adenocarcinoma, and thyroid carcinoma (Figure
5.4, Figure A.3). Although SL interactions are potential targets for cancer therapeutics in
some cancers, it would not be appropriate to use this strategy on all tumor types. Therefore,
targeting SL interactions of FBXW7 may have a wide opportunity for clinical application,
but must be used in conjunction with genetic testing and patient gene expression data.
In order to validate the novelty associated with the identified SL interactions in breast
cancer, we focused on SL interactions with FBXW7. Starting with FBXW7 our analysis
identified 32 SL interactions, many of which are proteasome components such as PSMB3,
PSMB4, PSMD2, PSMD7, and USP14. Given that FBXW7 is a E3 ubiquitin ligase, these
interactions highlight the genetic property of SL relationships where functional coherence is
often observed. As cyclin E is a substrate of proteasome degradation, it is interesting to
note that the recently published SL interaction between FBXW7 and CCNE1 may reflect
the interaction between FBXW7 and proteasome components [4]. Our ortholog mapping
is one-to-one and unfortunately, cyclin E falls into the“more than one ortholog” category
in yeast and “more than one corresponding ortholog” in humans, and as a result was not
included in HYGIN.
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Additionally, FBXW7 and PEMT are both separately down-regulated in breast cancer,
yet they share a proposed SL interaction in HYGIN. The gene expression ratios for all 114
patients for both FBXW7 and PEMT were evaluated to further investigate this finding.
Results showed that 20% of patients have gene expression ratios greater than 2-fold for both
FBXW7 and PEMT, and one patient has gene expression less than 4-fold for both genes.
This information suggested that the SL interaction between FBXW7 and PEMT is a false
positive result since the inhibition of both genes in a SL interaction should lead to cell death.
Our computational prediction suggested a SL interaction between FBXW7 and USP14,
a gene that codes for a deubiquitinating enzyme. FBXW7 has been proposed in the degra-
dation of a number of substrates including Aurora B [20, 117]. Although Aurora B kinase
is primarily degraded through the anaphase-promoting cyclosome complex (APC/c) [81],
negative regulation of Aurora B by FBXW7 plays an important role in Aurora B ubiqui-
tination and degradation [117]. USP14 is a major regulator of the proteasome and one of
three proteasome-associated deubiquitinating enzymes, which also affects protein turnover
in a substrate-specific manner [66]. Interestingly, a recent study has reported that over-
expression of USP14 stabilized and prevented Aurora B degradation through deubiquitina-
tion [108]. Furthermore, a FBXW7-Aurora B-p53 negative feedback loop has been suggested
[128]. This feedback loop suggests that a loss of FBXW7 leads to an increase in Aurora B,
which phosphorylates p53 and leads to MDM2 enhanced degradation of p53 and ultimately
cancer cell growth [128]. While the loss of FBXW7 may already stabilize Aurora B [20, 117],
over-expression of USP14 may be necessary for continued stability of Aurora B to maintain
cell-cycle progression and cell survival. Thus, consistent with our observation, loss of USP14
when FBXW7 is down-regulated may destabilize Aurora B, leading to a SL phenotype.
We also predict FBXW7 to exhibit SL interaction with a member of the pentose phosphate
pathway (PPP), ribulose-5-phosphate-3-epimerase (RPE), which catalyzes the reversible epimer-
ization of D-ribulose 5-phosphate to D-xylulose 5-phosphate. Interestingly, previous work
has shown that inhibition of the PPP results in decreased proliferation of tumor cell lines
[12, 13, 19, 21, 98]. In addition, it has also been shown that the PPP is essential for metabolic
network modulation to support tumor angiogenesis as inhibition of VEGFR-2 causes a de-
crease in PPP flux [126]. Thus, if inhibition of VEGFR-2 may decrease PPP flux, we hy-
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Figure 5.5: Gene expression data for FBXW7 was extracted from all cell lines studied
and cell lines were split into two categories: high FBXW7 expression and low FBXW7
expression. Here, a box plot shows FBXW7 expression in all cell lines; up-regulated
(red) and down-regulated (blue). The P-value (0.0079) represents the statistical differ-
ence between the two populations: cell lines with either high or low FBXW7 expression.
pothesized that inhibition of VEGFR should mimic the SL interaction between FBXW7
and RPE. To test this idea, we used drug response data from the cancerRXgene database
(https://www.cancerrxgene.org) and asked if cell lines deficient in FBXW7 are sensitive
to the VEGFR-2 inhibitor Cabozantinib. The cancerRXgene database contains data for 265
drugs and multiple cell lines and was examined to identify compounds that are more effective
when used selectively with cell lines that have a low FBXW7 expression. We found that cell
lines with low expression of FBXW7 were more sensitive to Cabozentanib (P-value = 0.033)
(Figure 5.5, 5.6), which supports the idea that inhibition of VEGFR should mimic the SL
interaction between FBXW7 and RPE.
Similarly, we also found a SL interaction between FBXW7 with ADA, an adenosine
deaminase that regulates cellular levels of adenosine and deoxyadenosine. ADA, along with
a few other enzymes (for example HGPRT), are responsible for purine metabolism and are
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Figure 5.6: Cell line gene expression data and cell line drug data (cancerRXgene database) were evaluated to identify to
which drugs low FBXW7 cell lines are susceptible. Drug kill curves in blue represent cell lines where FBXW7 is down-
regulated, and drug kill curves in red represent cell lines that have up-regulated FBXW7. Drug curves for Cabozantinib
(left), NSC-207895 (centre), and Selumetinib (right) were identified to have the greatest statistical significance between
cell lines with high and low FBXW7 gene expression.
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well known targets for cancer chemotherapy [38]. ADA can both degrade adenosine and
bind extracellularly to adenosine receptors to function as an allosteric modulator to regulate
adenosine. In fact, studies in a human astrocytoma cells have shown that manipulation of
cellular purine metabolite concentrations can make these cells more sensitive to apoptosis
[39]. While it remains to be explored if the astrocytoma cell line is deficient in FBXW7,
these studies indicate a potential role for ADA as a therapeutic target. Interestingly, previous
studies have shown that the expression of ADA is induced by growth factors like IGF in a Ras-
MAPK pathway dependent manner [134]. To test this idea, we used drug response data from
cancerRXgene database and asked if cell lines deficient in FBXW7 are sensitive to the MEK
inhibitor Selumitinib (Figure 5.6). Consistent with our SL observation, we found cells with
low expression of FBXW7 to be more sensitive to Selumitinib (P-value = 0.006). Thus, our
observation strongly indicates that FBXW7 can be used as a biomarker to indicate whether
to treat patients with drugs like Selumitinib that indirectly affects the expression of ADA.
Importantly, the availability of ADA inhibitors like 2‘deoxycoformycin (Pentostatin) that are
already in the clinics as standard chemotherapeutic agents for lymphoid malignancies[83]
may also represent a potential option to test our prediction. Indeed, analyses of the drug
data also indicates a potential opportunity for the MDM2 inhibitor NSC-207895 in treating
FBXW7 deficient cancers (P-value = 0.099, Figure 5.6). Using an MDM2 inhibitor to treat
FBXW7 deficient cancers is interesting because MDM2 is an negative regulator of p53 [64].
Previous research has also showed that FBXW7 is a transcription target of p53, and that
FBXW7 is dramatically up-regulated when p53 is introduced into p53-defficient cells by
adenovirus [62]. Therefore, if we use an MDM2 inhibitor, we would expect an increase in
p53 and subsequently an increase in FBXW7, which would mean that targeting FBXW7 SL
interactions would be not be effective in this instance. However, there is also evidence that
supports FBXW7 mediating the role of P53 in response to DNA damage [72]. As a result,
although the in silico drug analysis suggests that an MDM2 inhibitor would be a valuable
drug for treating FBXW7 deficient breast cancers, additional in vitro analyses are imperative
in order to understand what is going on inside the cell.
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Chapter 6
Discussion
In this thesis we describe a novel approach to identifying potential SL interactions in
breast cancer that uses a yeast SL interaction network, yeast-human gene ortholog informa-
tion, and patient gene expression data. Yeast is a common model organism and generating
a human orthologous network from a yeast gene network provides a major framework to ex-
tend yeast genetic interaction data to humans. When generating HYGIN, strict one-to-one
yeast-human ortholog mapping was used to avoid ambiguity as there are several instances
where a single yeast protein maps to multiple human orthologs, and vice versa. HYGIN is
cancer independent as no assumptions about cancer are made while generating the network.
As a result, any cancer gene expression data can be subsequently applied to generate cancer
type-specific subnetworks of genetic interactions. In this thesis we generate a breast cancer
specific subnetwork of HYGIN using breast cancer patient data from the TCGA.
6.1 Network generation
The development of HYGIN was based on previous work by Deshpande et al., but took
into consideration some of the problems with their network to generat a more robust and
strict network of human SL interactions [27]. Previously, Deshpande et al. generated two
networks: a complete SL network using all available orthologs in InParanoid, and a cancer-
specific network. The first network did not discriminate between any of the yeast-human
orthologs in InParanoid and simply applied any available orthologs (whether they were one-
to-one, one-to-many, many-to-one or many-to-many) to the yeast data. The second network,
used strict one-to-one yeast-human ortholog mapping network and contained cancer-relevant
mutation data. This thesis identified several discrepancies in their initial larger network
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related to problems with Ensembl identifiers, accession numbers, and gene names of the SL
interactions. Initially it was thought that these errors were the result of inconsistent book-
keeping. However, perspective and more information suggested that these mistakes are due
to changes in the databases (over the past 8 years) as well as updates to the human genome,
including characterization of previously uncharacterized genes and proteins. This brought to
light an interesting problem for HYGIN: how to make this research stand the test of time to
the best of our ability now? Researchers do not anticipate that entries in a database or a
reference table change over time or become deprecated; however, it was something to consider
when developing HYGIN: how to ensure that the network would be relevant in the future?
As a result, HYGIN has two reliable identifiers for each entry. In addition to the gene name, a
UniProtKB identifier is also present for each protein made from that gene. Since UniProtKB
is a fundamental bioinformatics database heavily utilized in current research, any deprecated
identifiers will be maintained in the database, with pointers to updated identifiers. At the
very least, deprecated identifiers will be recorded in the entry for a particular protein, and
that protein can still be located using the deprecated identifier as a search term.
The Deshpande et al. network also has 48 instances of non-canonical names used in the
common name list that contain either ‘-’ or ‘.’ and a version number as part of the name.
For example, the network contained the name “06-Mar”. It is known that this name can be
the result of automatic formatting when “MAR6” is typed into Excel [140]. It is still possible
that there are outliers in gene and protein accession lists that were used in this thesis, and
that there are minor mistakes in HYGIN. However, steps were taken to ensure that these
anomalies were minimized.
It is also worth discussing the differences in ortholog mapping between HYGIN and the
Deshpande et al. research. For example, in the instance where there are multiple human
orthologs for a single yeast protein, a corresponding node in the Deshpande et al. network
now represents multiple human proteins. If we are attempting to compare their network to
previously identified SL interactions, we are left with a challenge. All of the nodes can be
“unpacked” such that there is now a node representing each protein and a new edge from
each of these proteins to its SL partners. However, this “unpacking” of complex nodes can
drastically increase the number of edges and nodes in the network. In the case of the Desh-
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pande et al. network, the number of edges would quickly double from the addition of these
new edges resulting in a new network that has more than 50,000 edges. This would generate
a large number of potential falsely identified SL interactions in humans as well. However,
the second network generated by Deshpande et al. was a cancer-specific one that only used
one-to-one ortholog mapping for higher stringency. The potential problems identified in the
Deshpande et al. work was one of the motivations to use strict one-to-one ortholog mapping
for HYGIN.
Furthermore, HYGIN used the same cut-offs (P < 0.05 and  < −0.2) as the Deshpande
et al. network. However, they also used a relaxed cut-off (P < 0.05 and  < −0.08) for
SL interactions that were identified in reciprocal screens (where query A was crossed with
array B and vice veresa [22]). In our work to maintain stringency we maintained the same
cut-off (P < 0.05 and  < −0.2), irrespective of whether an interaction is identified in a
reciprocal screen or not. Their work was compared to HYGIN to determine if there were
more interactions identified in our work. Compared to Deshpande et al. [27] who identified
1,522 potential SL interactions in humans, we identified 10,419 interactions. Interestingly,
there are no SL interactions in common between these two networks. A potential reason
that HYGIN contains more SL interactions is that our study uses a more recent version of
The Cell Map database that includes interactions between essential and nonessential yeast
genes. Another reason is that their aim was to generate a SL gene network involving cancer-
relevant mutations in human cells. In contrast, our aim was to generate a SL gene network
in a cancer independent context, then apply cancer gene expression data to identify SL
interactions in breast cancer. As a result, the SL interactions in their network have cancer
relevant mutations, whereas no assumptions about cancer were made in the generation of
HYGIN.
6.2 Statistical analysis
There was trial and error involved in analyzing the TCGA data for the breast cancer sub-
network. Similar to the initial HYGIN, the initial analysis of the breast cancer data lacked
statistical validity. As a result, in order to have more confidence in our results, we applied
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strong statistical methods to the data which yielded a more concise breast cancer subnet-
work. The final methods for data analysis involved removing genes with any zero expression
values, evaluating an expression ratio for each gene for each patient, statistically determin-
ing if the expression was down-regulated (Wilcoxon signed-rank test), multiple hypotheses
adjustment (Benjamini-Hochberg procedure), and setting a cut-off value for genes identified
to be down-regulated in breast cancer (biological cut-off of 2-fold loss of expression).
An interesting result was observed while evaluating the breast cancer gene expression
data to determine genes that were down-regulated in breast cancer. The expression of the
15 genes that were identified to be in HYGIN and down-regulated in breast cancer were
also analyzed in 24 different cancer types. This analysis used pooled normal versus pooled
cancerous tissue in order to determine if a gene was statistically up- or down-regulated in
the other cancer types. Though previously it was discussed that a method using pooled data
is less stringent (Section 6.1), it is worth noting that in breast cancer, even when all 1,084
cancer samples were pooled and compared to all 100 normal samples, all 15 genes were still
statistically down-regulated. This could largely be due to sample size, and caution should
be taken when using this method for other cancer types that have fewer normal tissue gene
expression datasets. Using this data as a starting point to explore these 15 genes and their
SL interactions as methods of treatment in additional cancer types is promising.
6.3 Network validation
When validating HYGIN we used previously identified SL interactions in humans and took
an in silico approach to validation rather than an in vitro approach. Though in vitro work is
still required to successfully validate that the interactions in HYGIN are biologically relevant,
the in silico validation provides support for our results. Of the nearly 35,000 SL interactions
recorded in the SynLethDB, 5,830 were identified with DAISY, an in silico approach to the
identification of SL and synthetic dosage lethal (SDL) interactions in humans [58]. DAISY
uses both patient and cell line data to computationally predict SL and SDL interactions
using three inference strategies. Yet only 8 of these SL interactions identified by DAISY were
found in HYGIN. One explanation for this is that HYGIN is cancer independent. As a result,
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relying solely on yeast orthologs in humans and previously identified SL interactions in yeast,
human genes without yeast orthologs were excluded from our network. In contrast, DAISY
evaluated existing cancer gene expression data, cancer mutation data, and cancer cell line
data to computationally predict SL interactions. When comparing the number of genes in
each of the studies, HYGIN analyzes 1,009 genes and DAISY more than 20,000 genes. This
difference in sample size alone could account for the lack of overlap between the two studies.
However, it is interesting that DAISY did not predict more interactions between human
genes with known yeast orthologs. One reason for this could be the focus on cancer gene
expression, mutation, and cell line data that drive DAISY towards potential cancer-relevant
SL interactions and away from SL interactions involving non-cancerous genes.
There were also 1,020 SL interactions as a result of analyzing the shRNA data in the
DECIPHER database [45]. Since the DECIPHER database does not contain the genetic
information of healthy individuals, SL interactions predicted from the analysis of bi-specific
shRNA screens also have a tendency to identify SL interactions involving known cancer
oncogenes and tumor suppressors. Therefore, it is not surprising that there were only 3 SL
interactions identified in both HYGIN and DECIPHER given the cancer independent nature
of HYGIN, and the small number of patient-specific SL interactions identified in DECIPHER.
The 11 interactions from two separate sources provide evidence that there are SL inter-
actions in HYGIN that have been previously identified in humans. Although it would be
arduous to exhaustively test all 10,419 SL interactions in the network in vitro, these 11 sug-
gest that HYGIN has identified a potential 10,408 SL interactions between 1,009 genes that
have not previously been reported in the SynLethDB.
6.4 Breast cancer subnetwork
The breast cancer specific subnetwork contains several SL interactions involving genes that
were determined to be down-regulated in breast cancer patients. The subnetwork, and ul-
timately this subset of SL interactions, are an ideal starting point for in vitro and in vivo
validation studies and suggest novel targeted therapeutic strategies. Although there are only
130 interactions in the breast cancer subnetwork, validating all these interactions would be
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a time- and resource-consuming task. In contrast, additional in silico analyses is a more
cost- and resource-effective approach to identify SL candidates to test in vitro. By extracting
15 genes that were found to be down-regulated in humans and their SL partners, we can
target their SL partners with known or novel drugs to identify new treatment strategies on
a patient-by-patient basis.
The breast cancer specific interaction network produced 130 SL interactions between 15
genes down-regulated in breast cancer and their 115 SL partners. We further analyzed the 32
genes that have proposed interactions with the tumor suppressor FBXW7 and found that five
of those genes have previously identified drug inhibitors. The remaining genes that interact
with the 15 down-regulated genes in the breast cancer network are also potential targets for
further studies.
FBXW7 and PEMT are both down-regulated in breast cancer and they share a proposed
SL interaction in HYGIN. The gene expression ratios for all 114 patients for both FBXW7
and PEMT were evaluated to further investigate this finding. Results showed that 20% of
patients have gene expression ratios less than 2-fold for both FBXW7 and PEMT, and one
patient had gene expression less than 4-fold for both genes. There are two possibilities that
could explain this result. First, it is possible that at some point in evolutionary time this SL
interaction was valid. However, the cancer cells overcame the SL dependency of these two
genes in humans, and what we expect to manifest as cell death results in cell survival. Second,
it is possible that this result is a false positive. In light of a study that showed that there was
only 23% overlap in SL interactions between two species of the same genera (Saccharomyces
cereviseae and Saccharomyces pombe) [29], SL relationships are lost over evolutionary time.
Thus, we are expecting to see a loss of some SL interactions in our network as a result of
a larger species gap between Homo sapiens and Saccharomyces cerevisieae. Ultimately, this
result highlights the need for biological testing of predicted SL interactions prior to beginning
therapeutic trials. Though the HYGIN network is based on previous valid research methods,
human tissue behaves differently than predicted results.
The breast cancer specific network contains interactions that are valuable starting points
for SL research moving forward and provides numerous SL interactions for the scientific
community to study. The 15 genes that were identified to be down-regulated in breast cancer
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were also assessed in 24 other cancer types. Of the 15 genes, 11 of them were statistically
down-regulated in more than 15 cancer types including breast cancer (Figure A.4, A.5, A.6,
and A.7). Of note, HAAO, MGLL, and UPGE were down-regulated in 18 cancer types;
ADHFE1, CAT, and MSRA were down-regulated in 19; and RGN was down-regulated in 21
different types of cancer. This information suggests that SL interactions identified in breast
cancer for these genes would be extremely valuable to explore in other cancers as well. We
predict that in vitro and in vivo studies for these genes and their SL partners in cancer
models could lead to novel treatments for breast cancer that could be extended to other
cancer types.
6.5 Limitations of this study
Although in this thesis the HYGIN network was generated and validated, it is important
to address some of the limitations of this approach and how they impact this work moving
forward. First and foremost, it is important to acknowledge that the initial yeast dataset
represents a small portion of the potential interactions in the human genome. This was made
evident through the ortholog mapping, since only 1,009 yeast genes have strict one-to-one
human orthologs. As a result, we are essentially comparing approximately 16 - 20% of the
yeast genome to 5% of the human genome. This reduction in sample space is extremely
advantageous for saving time in the laboratory, but can result in overlooking numerous
potential SL interactions. Additionally, using strict one-to-one ortholog mapping also affects
the number of genes present in HYGIN. There are more than 1,000 additional yeast genes
that have one-to-many or many-to-one orthologous relationships with human genes. The
TCGA analysis eliminated any genes that had a non-zero value for any patient (either cancer
or normal datasets) which resulted in approximately 30% of human genes being excluded in
the breast cancer down-regulation analysis. Furthermore, using stringent P-value cut-offs and
a 2-fold cut-off for down-regulation also potentially excluded a number of potential genes and
their SL interactions from the analysis. Therefore, although this analysis identified potential
candidates for patient specific therapeutics, it very likely missed many other potential relevant
SL interactions, and there is room for expansion and improvement moving forward.
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Chapter 7
Future Work and Conclusions
7.1 Future Work
Throughout the work for this thesis a large amount of data was analyzed and used to generate
HYGIN and the breast cancer specific subnetwork. However, only a small portion of the
results were analyzed in great detail: FBXW7 and its SL partners. As a result, the remaining
14 genes down-regulated in breast cancer and their 105 SL partners, the remaining 1,730
genes down-regulated in breast cancer, and the remaining 10,289 SL interactions in HYGIN
were not analyzed in detail. This section discusses the potential future analyses of the data
generated through this project, potential caveats of future analyses and benefits to patient
care as a result.
7.1.1 Analyzing the 15 genes down-regulated in the breast cancer
subnetwork
In addition to evaluating the role of FBXW7 and its SL partners in breast cancer, future
work could also apply the same analyses to the remaining 14 genes that are down-regulated
in the breast cancer subnetwork. The range of SL partners for these 14 genes is 1 to 19,
with 7 genes having fewer than 5 SL partners (Figure A.3). Analyzing the 7 genes that
have more than 5 potential SL partners that can be used as drug targets (LDHD, HAAO,
ADHFE1, PEMT, AMT, UGP2, LARP6 ) could lead to additional treatment strategies for
breast cancer patients. Moreover, patients who have more than one of these genes down-
regulated in their tumor could benefit from combined drug therapy, which could increase the
effectiveness of treatment and recovery. The same method that was used to identify FBXW7
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deficient cell lines that were susceptible to known chemotherapeutics can also be applied to
these 14 genes. This analysis method would provide a similar amount of data for each of these
genes, which could lead to repurposing current therapeutics on a patient-by-patient basis.
This data could also provide insight into the mechanism behind some of the SL interactions
that were identified. Ultimately, however, this information could provide insight into which
genes are the best candidates for in vitro and in vivo studies moving forward by highlighting
genes that have the most clinical relevance and potential for success. Given that there are
130 SL interactions in the subnetwork, narrowing in on one or two genes to study in vitro
or in vivo would be resource- and time-efficient, especially if there was sufficient evidence to
support drug susceptibility in cell lines deficient in these genes.
7.1.2 Expand methods to other cancer types
Since the TCGA database has the same format for all of the cancer types and the Vizea-
coumar research group routinely downloads the most up-to-date version of all of the TCGA
data, running the same analysis on the remaining 23 cancer types in the TCGA is very
straightforward. However, the biggest challenge arises from the lack of normal data for some
of the cancer types. For this study, we were fortunate enough to be able to use the dataset
from the TCGA database with the most paired samples (114). Other cancer types in the
TCGA database have between 1 and 72 paired cancerous and normal samples. In instances
where there are 72 normal samples the argument could be made that sample size is large
enough for statistical validity. However, in instances where there are only one or two normal
samples, it is difficult to analyze the data with statistical confidence. As a result, analyzing
the remaining cancer datasets can be prioritized based on the number of paired samples
available. The breast cancer dataset had the largest number of paired samples, and the
next top 5 datasets are: kidney renal clear cell carcinoma (KIRK-US): 72 samples, thyroid
carcinoma (THCA-US): 58 samples, lung adenocarcinoma (LUAD-US): 55 samples, prostate
adenocarcinoma (PRAD-US): 52 samples, and liver hepatocellular carcinoma (LIHC-US): 48
samples. This data combined with the gene down-regulation data from breast cancer could
be very useful to evaluate how different cancer types (based on tissue) are similar (based
on genetic profiles). If we are able to classify tumors based on genetic profiles and exploit
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current therapies that are based on cancer type, there is the potential to repurpose several
clinically relevant chemotherapeutics for patient specific therapeutics.
7.1.3 The 1,745 genes down-regulated in breast cancer
Analysis of the TCGA data generated a list of 1,745 genes that were down-regulated in
breast cancer, of which only 15 were identified in HYGIN and used as the basis for the breast
cancer subnetwork. The remaining 1,730 genes that were identified have not been analyzed.
Potential further analyses include comparing these genes to the SynLethDB to see if any
of these genes have been identified to have SL partners in other studies or if other cancer
types are analyzed, comparing the set of down-regulated genes across cancer types in order
to identify common genes for novel drug development. They could also be used as a starting
point for SL analysis in vitro. Genes of interest could be screened against the entire human
genome in order to identify the complete set of SL interactions for any given gene that is
down-regulated in breast cancer. The results would provide valid drug targets that can be
exploited for patient therapeutics.
7.1.4 Additional FBXW7 analyses
The analyses surrounding FBXW7 in this thesis are mostly computational. Although the
drug data in the cancerRXgene database is from previous cell line experimentation, no wet
lab experimentation was completed directly for the purpose of this thesis. There has been
previous research that has identified SL interactions with FBXW7 in vitro [106], although
there was no overlap between the 32 SL interactions identified in this thesis and that study.
As a result, the natural progression for this research is to test FBXW7 and its SL interactions
in vitro and in vivo to provide biological evidence for these interactions.
7.2 Conclusion
Yeast genetic interaction data and orthology mapping was used to generate HYGIN, a hu-
manized SL interaction network, containing 10,419 proposed SL interactions between 1,009
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human genes. HYGIN improves on previous attempts to identify human SL interactions using
yeast data by using more stringent and rigorous analyses. Cancerous and normal tissue data
from the TCGA were evaluated to identify genes that were down-regulated in breast cancer.
The genes that were in HYGIN and down-regulated in breast cancer were used to generate
a breast cancer specific subnetwork containing 130 genes and 130 proposed SL interactions.
The tumor suppressor FBXW7 was identified to have the most SL interactions in the breast
cancer subnetwork and was selected for further study. In silico cell line and drug analysis
was used to identify potential drugs for therapeutics when FBXW7 is down-regulated. Given
that our hypothesis was to identify gene targets for breast cancer therapeutics, identifying 32
potential novel drug targets for FBXW7 deficient breast cancers makes this project a success.
These findings provide the basis for further testing of SL interactions with FBXW7 in vitro
and in vivo to validate them for potential patient therapeutics.
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Apoptosis 5 6 20 0 6 21 17 6 13 6 8 1 26 0 9 0 32 3 12 0 18
Cell	Cycle	and	Mitosis 45 55 157 11 22 197 117 62 52 69 89 12 176 19 49 6 372 17 61 5
Cell	adhesion	and	communication 3 1 3 0 1 7 4 3 2 1 1 0 4 0 2 0 2 0 0
Chaperone	and	Protein	Folding 29 4 42 5 21 29 36 16 27 18 41 2 77 7 25 1 67 56
Cytoskeleton 9 6 23 2 4 36 19 6 13 10 23 1 33 0 23 1 14
DDR	pathways	and	NA	metabolism 75 53 163 22 32 248 201 57 123 60 135 13 245 18 94 17
Developmental	Process 5 3 4 1 6 13 12 2 8 0 8 1 14 0 3
Enzymatic	or	Catalytic	Activity 22 32 46 2 29 78 49 38 52 46 97 1 225 5
Immune	System	process 5 3 23 1 2 22 30 8 9 4 20 2 20
Intracellular	Protein	Traffic 105 72 149 6 56 173 126 114 101 104 201 5
Ion	Regulation 4 3 9 0 1 8 3 2 11 1 6
Metabolism 45 37 106 4 34 144 78 48 83 36
Miscellaneous 23 9 34 3 14 81 45 26 23
Mitochondrial	Organization 37 25 59 4 13 102 53 36
Protein	Modification 22 18 61 4 11 58 37
RNA	Processing 64 26 120 7 31 218
Ribosomal	Biogenesis	and	Translation 84 55 173 10 47
Signal	transduction 20 8 23 0
Stress	Response 1 1 4
Transcription	and	Chromatin-related 55 34
Transport 16
Figure A.1: 22 GO Slim terms and the interactions between them as translated from yeast are represented in this
table. Cells are colour-coded according to the number of interactions between two groups of GO terms, where darker cells
represent more interactions and lighter cells represent fewer interactions.
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AB
Supplementary Figure S2
Figure A.2: Two searches of the InParanoid database were conducted to verify that FBXW7 has a strict one-to-one
mapping. A) The human genome was searched for the protein MET30 (the yeast protein that is orthologous to FBXW7
in humans). As expected, a single ortholog mapping was identified between Saccharomyces cerevisiae and Homo sapiens.
B) The protein CDC4, a synonym for FBXW7, in humans was subsequently searched for in humans. Finding no ortholog
in human, InParanoid reported ”hits” in other organisms. Results showed that there is no entry for CDC4 in humans,
which means that there is no additional FBXW7 ortholog in Saccharomyces cerevisiae.
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	ABCG2	 5.88E-05 2.48E-46 2.15E-06 2.06E-25 NS NS 5.88E-04 4.82E-02 9.48E-07 7.70E-15 5.47E-12 4.36E-31 4.88E-24 2.22E-02 1.14E-11 2.28E-07 1.48E-03 7.29E-04 9.46E-20
	ABHD6	 3.12E-04 3.84E-39 3.22E-06 4.48E-22 6.29E-04 1.02E-03 NS 6.60E-06 NS NS 6.36E-21 7.45E-30 6.47E-22 1.07E-02 2.57E-18 1.55E-05 1.24E-10 7.18E-11 2.16E-09
	ADHFE1	 8.84E-08 1.06E-54 2.15E-06 3.44E-25 1.15E-06 9.57E-04 3.12E-09 4.57E-06 4.22E-26 NS 5.55E-14 9.48E-14 2.31E-17 5.58E-03 NS 2.93E-07 3.84E-16 2.33E-14 6.87E-17
	AIFM2	 NS 1.47E-30 NS 9.61E-03 NS NS NS 3.22E-10 7.76E-05 2.87E-02 1.03E-12 6.83E-13 NS 1.10E-02 2.68E-15 NS 6.47E-03 1.00E-12 4.49E-12
	AMT	 5.01E-04 1.90E-34 2.15E-06 6.14E-15 1.74E-05 NS NS 2.21E-07 6.21E-29 4.58E-08 4.05E-12 NS 4.26E-11 NS 4.87E-12 1.67E-02 3.73E-10 4.75E-02 2.00E-03
	CAT	 2.20E-05 1.16E-60 2.15E-06 8.34E-19 1.71E-04 1.17E-02 3.51E-07 NS 8.33E-34 1.28E-16 9.87E-25 1.29E-35 5.58E-32 1.66E-03 2.19E-09 6.83E-05 1.13E-08 2.62E-02 4.11E-07
FBXW7 2.37E-02 3.48E-57 4.50E-04 2.17E-02 4.87E-03 8.77E-05 1.56E-12 4.58E-05 4.88E-20 7.95E-06 1.09E-05 1.60E-02 4.53E-02 2.59E-03 3.69E-06 1.38E-02 3.09E-04 1.08E-12 8.50E-07
	HAAO	 6.77E-12 3.16E-40 2.15E-06 1.74E-03 NS 5.75E-03 1.08E-08 6.29E-10 9.83E-06 9.35E-03 3.65E-19 1.90E-09 1.50E-09 3.38E-02 1.21E-14 NS 1.94E-03 6.98E-04 2.63E-17
	LARP6	 8.70E-05 2.46E-53 3.56E-05 NS 1.88E-03 9.77E-05 6.33E-04 3.42E-06 3.86E-11 1.74E-02 3.96E-03 1.13E-07 3.13E-10 2.68E-03 8.67E-04 NS 2.78E-07 NS 5.28E-11
	LDHD	 NS 7.42E-31 2.15E-06 1.37E-25 4.23E-05 9.77E-05 3.86E-19 1.09E-07 6.10E-31 9.57E-04 6.55E-23 1.14E-05 9.66E-13 1.13E-02 NS 4.31E-07 2.96E-10 4.94E-17 NS
	MGLL	 4.90E-11 6.02E-46 2.05E-02 8.72E-24 4.79E-02 1.37E-03 1.33E-22 NS 2.57E-21 3.27E-02 2.38E-12 1.53E-15 2.31E-31 2.99E-02 3.74E-05 1.55E-05 9.14E-07 1.45E-02 5.21E-07
	MSRA	 7.13E-05 1.91E-49 2.15E-06 4.22E-14 5.80E-05 2.11E-02 2.15E-17 8.65E-09 7.74E-08 4.80E-09 1.68E-22 4.08E-19 1.34E-30 1.71E-02 6.22E-06 3.87E-04 2.55E-10 7.84E-12 3.88E-02
	PEMT	 5.19E-05 8.23E-20 2.15E-06 2.19E-15 1.92E-02 9.00E-04 2.92E-02 9.87E-04 2.86E-02 1.47E-06 3.51E-22 4.40E-02 NS NS 4.59E-03 4.77E-05 NS 3.71E-15 2.11E-03
	RGN	 1.61E-09 4.13E-52 2.15E-06 2.35E-06 7.82E-06 NS 2.07E-14 7.61E-03 4.79E-19 8.57E-10 3.80E-19 4.48E-17 1.02E-30 1.61E-03 4.03E-15 1.57E-03 3.31E-10 4.50E-11 1.32E-16
	UGP2	 2.17E-05 1.36E-46 2.15E-06 2.41E-26 1.14E-04 1.58E-02 6.27E-16 2.62E-03 4.67E-15 6.75E-05 3.98E-20 4.26E-05 NS 1.50E-03 1.49E-09 1.31E-07 4.34E-08 5.93E-08 1.22E-05
Figure A.3: The 15 genes that are the basis for the breast cancer subnetwork were analyzed across 24 different cancer
types. The 19 cancer types where the majority of the 15 genes are down-regulated are depicted here. Significant values in
blue denote statistically significant lower expression in pooled cancer tissue when compared to pooled normal tissue, values
in red denote statistically higher expression in cancer, and NS values denote a non-significant change in gene expression
between cancer and normal tissues. All P-values were calculated using the Mann-Whitney U test.
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Supplementary Figure S4
Figure A.4: Gene expression calculated by RNA-seq by Expectation-Maximization
(log2) for ABCG2, ABHD6, ADHFE1, and AIFM2 for 24 different cancer types compar-
ing cancer and normal samples within the same tissue type. Box plots are colour-coded
in pairs based on cancer type where the boxplot on the left is gene expression in cancer
and the plot on the right is gene expression in normal tissue. Labels on the x-axis
represent the abbreviation of the cancer type, whether the sample represents tumor
(T) or normal (N) tissue, and the sample size.
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Supplementary Figure S5
Figure A.5: Same as description for Figure A.4, except for AMT, CAT, HAAO, and
LARP6.
81
BL
CA
-N
-1
9
BL
CA
-T
-4
05
BR
CA
-N
-1
00
BR
CA
-T
-1
08
4
CE
SC
-N
-3
CE
SC
-T
-2
97
CH
OL
-N
-9
CH
OL
-T
-3
6
CO
AD
-N
-4
1
CO
AD
-T
-4
76
ES
CA
-N
-1
1
ES
CA
-T
-1
73
GB
M
-N
-5
GB
M
-T
-1
45
HN
SC
-N
-4
4
HN
SC
-T
-5
15
KI
CH
-N
-2
5
KI
CH
-T
-6
6
KI
RC
-N
-7
2
KI
RC
-T
-5
27
KI
RP
-N
-3
2
KI
RP
-T
-2
89
LI
HC
-N
-5
1
LI
HC
-T
-3
69
LU
AD
-N
-5
8
LU
AD
-T
-5
12
LU
SC
-N
-5
1
LU
SC
-T
-4
98
PA
AD
-N
-4
PA
AD
-T
-1
78
PC
PG
-N
-3
PC
PG
-T
-1
76
PR
AD
-N
-5
1
PR
AD
-T
-4
83
RE
AD
-N
-1
0
RE
AD
-T
-1
63
SA
RC
-N
-2
SA
RC
-T
-2
58
SK
CM
-N
-1
SK
CM
-T
-1
04
ST
AD
-N
-3
5
ST
AD
-T
-4
13
TH
CA
-N
-5
7
TH
CA
-T
-5
00
TH
YM
-N
-2
TH
YM
-T
-1
20
UC
EC
-N
-3
5
UC
EC
-T
-5
40
PEMT
MSRA
MGLL
4
6
8
10
12
6
8
10
12
14
2
4
6
8
10
12
14
-2.5
0.0
2.5
5.0
7.5
12.5
Ge
ne
 e
xp
re
ss
io
n
10.0
LDHD
2
Supplementary Figure S6
Figure A.6: Same as description for Figure A.4, except for LDHD, MGLL, MSRA,
and PEMT.
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Supplementary Figure S7
Figure A.7: Same as description for Figure A.4, except for RGN and UPG2.
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Appendix B
Supplementary Tables
Supplementary tables included as comma separated value (csv) files. Table legends for
each are provided below.
Supplementary Table B.1: Strict one-to-one ortholog mapping for yeast genes in hu-
mans. Ortholog mapping information was taken from InParanoid and filtered to identify
instances where one yeast protein mapped to one human protein. The resulting 1,266 pairs
of orthologs can be found in this table.
Supplementary Table B.2: HYGIN network table. This table contains the initial
mapping data from the yeast network where SL interactions are represented in pairs by A
and B (Yeast Gene ID A, Yeast Gene ID B, Yeast Gene Name A, Yeast Gene Name B,
eValue, and pValue). Through the 3-stage mapping process used to generate HYGIN, it
also contains columns corresponding to Yeast Protein Accession (A and B), Human Protein
Accession (A and B), and Human Gene Name (A and B). Human gene names were used
to generate the network in Cytoscape. Due to some reciprocal screens in the initial yeast
screen, there were some duplicate (reciprocal) entries in this table. Once the network was
loaded into Cytoscape,“Remove duplicate edges” was used to eliminate reciprocal hits. This
resulted in the 1,009 genes and 10,419 edges in the final HYGIN network.
Supplementary Table B.3: GO Slim mapping table. Twenty-two GO Slims were used
for colouring the HYGIN network in Cytoscape. These terms were curated by and courtesy of
the Vizeacoumar research group. The common name for the human protein and its accession
number accompany the GO Slim terms that have been curated by the Vizeacoumar research
group. *DDR Pathways = “DNA Damage and Repair Pathway” and NA Metabolism =
“Nucleic Acid Metabolism”.
Supplementary Table B.4: List of genes that were identified as down-regulated in
breast cancer at a 2-fold cut-off and with a Wilcoxon Signed Rank P-value less than 0.05.
Mean expression is the average of the log(2) ratio (cancer gene expression/normal gene expres-
sion) for each gene. P-values are from Wilcoxon Signed Rank test (Python) after adjustment
(Benjamini-Hochberg procedure), and log(10)(P-values) were used to generate the volcano
plot in Figure 5.3.
Supplementary Table B.5: Genetic interactions in the breast cancer subnetwork. The
table contains a list of the SL gene pairs that make up the breast cancer specific subnetwork
where column GeneA represents the genes that are down-regulated in breast cancer, and
column GeneB are their SL gene pairs.
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Appendix C
Permission to Reprint
This section contains the permission to reprint three figures that are present in this thesis.
C.1 Figure 2.1
Attached is the permission from Nature Reviews Genetics to replicate Figure 1 from Welcker
and Clurman [130].
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C.2 Figure 2.2
Attached is the permission from Cell Press to replicate Figure 1 from Paul et al. [89].
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C.3 Figure 2.3
Attached is the permission from European Journal of Cancer to replicate Figure 1 from
Ferrari et al. [34].
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